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Wataru Yamamoto 
 
ENDOPLASMIC RETICULUM CALCIUM DINAMICS AND INSULIN SECRETION IN 
PANCREATIC β CELLS  
 
Under normal conditions, ER Ca2+ levels are estimated to be at least three orders 
of magnitude higher than intracellular Ca2+. This steep Ca2+ concentration gradient is 
maintained by the balance of Ca2+ uptake into the ER via the sarco-endoplasmic 
reticulum Ca2+ ATPase (SERCA) pump and ER Ca2+ release through Ryanodine 
receptors (RyR) and Inositol 1,4,5-triphosphate (IP3) receptors (IP3R).  Emerging data 
suggest that alterations in β cell ER Ca2+ levels lead to diminished insulin secretion and 
reduced β cell survival in both type 1 and type 2 diabetes.  However, the mechanisms 
leading to β cell ER Ca2+ loss remain incompletely understood, and a specific role for 
either RyR or IP3R dysfunction in diabetes has been largely untested.  To this end, we 
applied intracellular and ER-Ca2+ imaging techniques in INS-1 β cells and isolated 
mouse and human islets to define whether RyR or IP3R activity were altered under 
diabetogenic conditions.  Results revealed preferential alterations in RyR function in 
response to ER stress, while pro-inflammatory cytokine stress primarily impacted IP3R 
activity. Consistent with this, pharmacological inhibition of RyR and IP3Rs prevented ER 
Ca2+ loss under ER and pro-inflammatory stress, respectively.  However, RyR inhibition 
was unique in its ability to prevent β cell death, delayed initiation of the unfolded protein 
response (UPR), and dysfunctional glucose-induced Ca2+ oscillations in tunicamycin-
treated INS-1 β cells and islets from Akita mice.  Monitoring at the single cell level 
revealed that ER stress acutely increased intracellular Ca2+ transients and this was 
dependent on both ER Ca2+ leak from the RyR and plasma membrane depolarization, 
suggesting ER Ca2+ dynamics regulate cellular excitability. Collectively, our findings 
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suggest that ER-stress induced RyR dysfunction regulates β cell ER Ca2+ dynamics, 
propagation of the UPR, insulin secretion, and cell survival.  These data indicate that 
RyR-mediated loss of ER Ca2+ and β cell hyperexcitability may be early pathogenic 
events in diabetes. 
 
Carmella Evans-Molina, M.D., Ph.D, Chair 
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Chapter 1. Introduction 
1.1 Diabetes Mellitus and Pancreatic β Cells 
Diabetes Mellitus is an important public health concern that affects the health and 
prosperity of individuals throughout the world.  According to data from the International 
Diabetes Federation, 415 million adults aged 20-79 were affected by diabetes in 2015, 
whereas another 318 million adults had impaired glucose tolerance with an associated 
increased risk of developing diabetes (1). Moreover, the number of adults with diabetes 
is expected to increase to approximately 642 million in 2040, accounting for nearly 1 in 
10 individuals. Annually, diabetes is estimated to cause over 5 million deaths, and the 
financial burden of this disease is enormous. It is estimated that diabetes accounts for 5 
– 20% of the total health care expenditures of an individual country. In the US, 29.3 
million adults had diabetes in 2015, and diabetes-related expenditures were estimated at 
320 millions US dollars. To reverse these trends, improvements are needed in the 
prevention, diagnosis, management, and treatment of diabetes. Given the close 
association between obesity and Type 2 diabetes, continued efforts focused on lifestyle 
and improvements in nutrition are required.  To stem the tide of Type 1 diabetes, an 
improved understanding of disease triggers and the identification of agents that both 
prevent immune activation and improve the health of the β cell will be needed.   
The research in this thesis will explore the mechanisms underlying failure of 
pancreatic β cells in diabetes with an emphasis on dysregulated calcium storage in the 
endoplasmic reticulum, an intracellular organelle that is crucial for insulin biosynthesis by 
the pancreatic β cell and normal control of blood glucose. 
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1.1.1 The main forms of Diabetes: Type 1 and Type 2 Diabetes Mellitus 
The hallmark of diabetes mellitus is an elevated blood glucose level 
(hyperglycemia) that occurs secondary to either a complete or relative deficiency of 
insulin secretion and/or insulin action. Insulin is a hormone produced solely by the 
pancreatic β cells that activates glucose transport into cells via glucose transporters, 
where it is utilized as a source of energy. In the case of insulin deficiency or impaired 
insulin action, peripheral tissues cannot efficiently take up glucose. The resulting 
hyperglycemia damages a number of tissues, resulting in diabetic macrovascular 
complications (i.e heart disease and stroke) and several microvascular complications, 
including, kidney failure, retinopathy, and neuropathy.  
Diabetes is a heterogenous disease, rarely caused by single gene mutations (2) 
and is typically caused by a diverse input of many modest influences dictated by 
environment, lifestyle, aging, and genetics. The two main subtypes of diabetes are 
phenotypically categorized as Type 1 and Type 2 diabetes mellitus (3,4). Type 1 
diabetes (T1DM) is an autoimmune disease characterized by auto-immune mediated β 
cell destruction and a nearly complete absence of insulin production. T1DM accounts for 
5 – 10% of all cases of diabetes. To regulate blood glucose and decrease diabetes-
associated complications, persons with T1DM must administer multiple daily injections of 
exogenous insulin or wear an insulin pump that delivers continuous insulin infusions 
subcutaneously (5).  
T1DM is characterized by β cell destruction that is mediated by islet infiltrating 
autoreactive immune cells (6).  The mechanism of T1DM is not fully understood.  
However, it is generally accepted that insufficient T regulatory cells (Treg) suppression 
of effector T cells (Teff) that target the β cells is an early pathogenic event in T1DM (7).   
More recently it has been appreciated that β cell failure also contributes to T1DM 
pathogenesis (8).  Clinically, T1DM is typically first detected by the onset of severe 
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hyperglycemia that may also be accompanied by ketoacidosis.  A hallmark of T1DM is 
the presence of circulating autoantibodies against key autoantigens including insulin, 
islet antigen 2 (IA2), glutamic acid decarboxylase (GAD), and zinc transporter 8 (ZnT8).  
Individuals at risk of developing T1DM are identified by the presence of these 
autoantibodies at a time prior to the onset of clinically significant hyperglycemia (9).  
What triggers the autoimmune attack against the β cells in T1DM remains 
unclear. However, T1DM is thought to arise in genetically susceptible individuals in 
response to an environmental or viral triggering event that initiates the autoimmune 
response. A family history of T1DM plays an important role in determining risk.  For first-
degree relatives, the risk of T1DM is estimated to be approximately 3 – 8%, depending 
on whether an individual’s mother, father, or a sibling has T1DM (10,11). In addition, 
human leukocyte antigen serotype HLA-DR3-DQ2 and HLA-DR4-DQ8 class II 
haplotypes are known to be robustly associated with T1DM, and 90% of children with 
T1DM have one or both of these haplotypes (12,13). Other than the HLA Class II locus, 
other genetic variants have been associated with T1DM risk.  These include differences 
in the variable number of tandem repeat regions in the insulin gene (14) and 
polymorphisms in the CTLA-4 gene that negatively regulate immune responses (15), 
variants in protein tyrosine phosphatase, non-receptor type 22, PTPN22, encoding the 
lymphoid protein tyrosine phosphatase that negatively regulates the T-cell receptor (16), 
and IL2RA that forms the IL-2 receptor complex with CD25 expressed on activated T-
cells and on regulatory T-cells (Tregs) (17). 
The pathogenesis of T1DM begins with the interactions of the innate and 
adaptive immune system with β cells. Initially, islet resident antigen presenting cells 
(APCs) such as macrophages and dendritic cells receive and process islet antigens. As 
a consequence, APCs migrate to pancreatic lymph nodes (15). Within the lymph nodes, 
islet antigens are presented to and activate naïve circulating autoreactive T cells.  This 
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causes T cell activation and initiates immune cell infiltration into the islet (18).  Increased 
levels of pro-inflammatory and toxic cytokines and chemokines are released from 
resident APCs, infiltrating T cells, and the β cells themselves, causing additional immune 
cell recruitment into the islet (19).  These cytokines indirectly cause β cell death, while 
further β cell death occurs through direct interactions between CD8+ T cells and the β 
cell (20,21).  
Currently a number of prevention efforts are being tested in individuals who 
already have established autoimmunity and autoantibody positivity.  Prevention efforts 
are also being tested in birth cohorts identified on the basis of genetic risk, who are then 
followed longitudinally to identify both environmental contributors as well as patterns of 
immune activation before and after antibody seroconversion (5). Studies include the 
Environmental Determinants of Diabetes in the Young (TEDDY) (22), Baby Diabetes 
(BABYDIAB) (23), Diabetes Prediction and Prevention Project (DIPP) (24), and the 
double-blind, placebo-controlled, dose-escalation, phase 1/2 clinical pilot study (Pre-
POINT studies) (25). 
A number of recent studies have also tested immunomodulatory therapies to 
either prevent T1DM. These include efforts focused on restoration of tolerance (26,27), T 
cell or B cell inhibition (28), Treg induction (29), suppression of innate immunity and 
inflammation (4,30), immune system reset (31), and islet transplantation (32). Trials 
have tested antigen-specific therapies to induce immune tolerance (33), monoclonal 
antibodies (28,34,35) and fusion proteins (36,37) that target specific immune cells, and 
strategies to alter the effector T cell (Teff)/Treg balance. Overall, each treatment has 
limited duration of effect, and no single therapy has stopped the autoimmune attack on β 
cells.  
Given these disappointing outcomes, there has been a recent emphasis on 
testing a combination of therapies at T1D onset. (6).  Additionally, there is an emphasis 
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on testing prevention efforts in individuals who already have established autoimmunity 
and autoantibody positivity, but lack clinical hyperglycemia.  Prevention efforts are also 
being tested in birth cohorts identified on the basis of genetic risk, who are then followed 
longitudinally to identify both environmental contributors as well as patterns of immune 
activation before and after antibody seroconversion (5).  
 
Type 2 diabetes (T2DM) is the most common form of diabetes and accounts for 
90 – 95% of all diabetes cases. Similar to T1DM, the exact cause of this disease is still 
unknown but risk factors include obesity, poor nutrition, physical inactivity, smoking, (38) 
and a variety of genetic factors (3,38). Classically, T2DM begins with peripheral insulin 
resistance, in which glucose uptake and the metabolic effects of insulin are decreased in 
all tissues in body (39). In the setting of obesity, insulin resistance, and high fat diet lead 
to increased release of free fatty acids from the adipose tissue, which further exacerbate 
glucose uptake into muscle.  A second key contributing factor is increased 
gluconeogenesis at the level of the liver that also worsens hyperglycemia (40).   
Initially, β cells are able to overcome insulin resistance through increased insulin 
production and secretion. However, as T2DM progresses, β cell dysfunction ensues and 
insulin secretion from the β cells begins to diminish (41). In addition to gluco-lipotoxicity 
as a primary cause of β cell failure (42), emerging areas of research have focused on 
pathways leading to pro-inflammatory stress or ER stress (43), and oxidative stress in 
the β cells (44). Recently, dedifferentiation, which is defined as loss of expression of key 
β cell specific genes has been proposed as a cause of T2DM (45,46). 
Genome-wide association studies (GWAS) have identified a number of risk 
variants associated with T2DM risk. Susceptibility loci identified to date have primarily 
been linked to the regulation of β cell function (38).  For example, polymorphisms have 
been identified in the KCNJ11 gene that encodes the potassium inwardly rectifying 
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channel subfamily J, member 11 (38,45-47). In addition, variants in TCF7L2 have been 
identified. This gene encodes the ubiquitous transcription factor 7-like 2 (48), a mediator 
of Wnt signaling (49) and inhibitor of insulin secretion (50)  Polymorphisms have also 
been identified in the IRS1 gene that encodes insulin receptor substrate 1.  IRS1 plays a 
role in β cell health and function as wells as peripheral insulin signaling (51). Islets from 
IRS1 knock-out mice and IRS1 deficient β cells exhibited decreased in insulin content 
and reduced glucose stimulated insulin secretion (52). Variants in MTNR1B gene, which 
encodes the melatonin receptor 1B, is thought to increase the risk of T2DM by inducing 
impaired early insulin secretion (53).  
Polymorphisms have also been identified in genes with more pleiotropic 
metabolic effects. The PPARG2 gene encodes peroxisome proliferator-activated 
receptor gamma (PPAR-γ) 2, which is a member of the nuclear hormone receptor 
subfamily.   PPAR-γ is thought to regulate insulin action, but has also been shown to be 
expressed in the β cell.  Agonists of PPAR-γ improve insulin sensitivity and have been 
associated with improved β cell function.  Our lab has previously shown that PPAR-γ 
regulates transcription of the ER Ca2+ transporter Sarco-endoplasmic reticulum Ca2+ 
ATPase (SERCA) 2 level in the β cell, leading to improved β cell Ca2+ signaling and ER 
Ca2+ storage (54), which will be discussed later.  Additional risk variants have been 
identified in the IGF2BP2 gene that encodes the insulin-like growth factor two binding 
protein 2 and regulates translation of the insulin-like growth factor 2 (IGF2), and the fat 
mass and obesity-associated gene, FTO, which is associated with obesity and weight 
gain (55). 
1.1.2 Therapy for Type 1 and Type 2 Diabetes Mellitus 
The treatment of T2DM is complicated and often requires multiple agents to 
achieve glycemic control. Treatment is typically initiated with an oral agent, and the first 
line agent for most newly diagnosed individuals with T2DM is the biguanide metformin 
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(56). The precise molecular mechanisms of metformin action are not fully understood.  
However, this drug is thought to primarily lower blood glucose levels by reducing hepatic 
glucose output through reduced gluconeogenesis. The use of metformin has also been 
associated with increased insulin induced glucose uptake and increased glycogenesis in 
skeletal muscle (57). Metformin has been shown to regulate the expression of genes 
related to hepatic gluconeogenesis through activation of AMP-activated protein kinase 
(AMPK) (58,59). Additionally, recent data have shown that metformin inhibits 
mitochondrial glycerophosphate dehydrogenase (GPDH) to alter the hepatocellular 
redox state, which result in reduced gluconeogenesis (60). Other advantages using 
metformin include reduced cardiovascular events, decreased mortality (61,62), and 
lower risk of hypoglycemia using this drug (63). 
Other commonly utilized oral agents include sulfonylureas, which close the ATP-
sensitive potassium channel of the pancreatic β cells to stimulate insulin secretion (64). 
However, the effect of sulfonylureas depends on the presence of enough functional β 
cells to increase insulin secretion, and diabetes progression is typically associated with 
failure to respond to sulfonylureas. Adverse effects of these medications include an 
increased risk of hypoglycemia (65) and weight gain. The risk of hypoglycemia is higher 
for older persons with impaired renal and hepatic function (66). 
 Incretins are a group of hormones that decrease blood glucose levels by 
promoting insulin secretion. Incretin-based therapies have been introduced in recent 
years. The incretin hormones include glucagon-like peptide-1 (GLP-1), primarily arise 
from the intestinal enteroendocrine L cells (67), and glucose-dependent insulinotropic 
polypeptide (GIP), which are released in response to a meal, leading to increased insulin 
secretion. Incretin secretion is dramatically diminished in T2DM (68,69). In T2DM, 
administration of spraphysiological amounts of GLP-1 can lead to enhanced glucose-
stimulated insulin secretion, whereas administration of GIP does not induce insulin 
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secretion regardless of the concentration utilized (70). Therefore, GLP-1 is 
therapeutically more favored than GIP, and inhibitors of dipeptideyl peptidase-4 (DPP-4), 
the enzyme that degrades GLP-1, have been developed for clinical use (71,72). 
Plasma levels of GLP-1 are relatively low compared to other hormones, and 
GLP-1 has a very short half-life due to DPP4 activity. GLP-1 is metabolized within 1 
minute around the L cells (73,74), which generated considerable controversy as to the 
source of GLP-1 that acts on distant organs such as the pancreatic β cells. Recently, an 
updated model was proposed whereby GLP-1 derived from the L cells activates neurons 
to regulate insulin secretion, and GLP-1 derived from islet α cells serves as paracrine 
factor to induce insulin secretion in β cells (75).  
As described, GLP-1 has a short half-life due to DPP-4 activity, so the effects of 
GLP-1 by subcutaneous injections were very short-lasting (76). That led to the 
development of inhibitors of DPP-4, or stable DPP-4 resistant GLP-1 analogs (77). 
Exendin 4, isolated from Heloderma suspectum, is a peptide that has 50% sequence 
homology to GLP-1. This peptide was found to be resistant to DPP-4 activity and is 
eliminated only by glomerular filtration by the kidney (78), thereby increasing the plasma 
half-life of Exendin 4 to as long as 30 minutes (79). 
Other orally active agents include α-glucosidase inhibitors, which inhibit 
breakdown and digestion of carbohydrates in the intestine, and thiazolidinediones (TZD), 
which activate PPARs, including PPAR gamma.  These agents are less widely utilized 
and their clinical effects are summarized in Table 1. A large percentage of individuals 
with T2DM will eventually fail oral agents and incretin-based therapies and require 
insulin injections as β cell failure ensues (3). 
A recent option to treat diabetes in morbidly obese patients is bariatric surgery, 
which either reduces the size of stomach to decrease food intake or re-routes the small 
intestine to cause malabsorption (80). Clinical studies show that blood glucose is often 
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normalized within a week of surgery, even prior to significant weight loss.  At present, 
the exact mechanisms of improved glycemia in the short-term are not well understood 
but it is hypothesized that surgery leads to either increased release of GLP-1, alterations 
in gut microbiota, and the anticipated metabolic effects of acute and severe caloric 
restriction peri-operatively (3). 
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Table 1. Drug Treatment for Type 2 Diabetes 
Class Name Drug Name Target Action  
α-glucosidase 
inhibitors (AGIs) 
Acarbose 
Miglitol 
Voglibose 
α-glucosidase Carbohydrate 
absorptionê 
No weight gain 
 
Biguanides Metformin AMPK Blood glucoseê (60,61) 
  GPDH  Insulin actioné  
  (Still debated) Hepatic outputê  
   Cardiac riskê  
   Hypoglycemia Riskê  
   No weight gain  
GLP-1 Analog Exenatide GLP-1R Insulin secretioné (81) 
 Liraglutide  Glucagon secretionê  
   Satietyé  
   Hypoglycemia Riskê  
   No weight gain  
Sulfonylurea Glyburide 
Glipizide 
Gliclazide 
Glimepiride  
KATP channels Insulin secretioné 
Weight é 
(65) 
Thiazolidinedion
e 
Troglitazone  PPAR-γ Insulin actioné  (82) 
(TZDs) Roziglitazone  Hypoglycemia Riskê  
 Pioglitazone  Weight é  
   Glycemic controlé  
Insulin Lispro Direct target Blood glucoseê  
 Aspart  Weight é  
 Glulisine    
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1.1.3 Pancreatic islet β cells, and other cell types 
The endocrine pancreas consists of the islets of Langerhans that make up about 
~5% of the total pancreatic mass. The endocrine islets were named for the German 
physician Paul Langerhans, who discovered the cells that secrete insulin.  Islets consist 
of aggregates of ~1000 different cells.  The insulin producing β cells make up ~75% of 
cells found in the islet.  Additional cell types found in the islet include α cells, δ cells, PP 
cells and ε cells. The α cells consist of ~20% of total islet cells (83), and secrete 
glucagon. Glucagon is described as a counter-regulatory hormone to the effects of 
insulin and acts to raise blood glucose levels.  Glucagon promotes gluconeogenesis in 
the liver and induces fatty acid oxidation and ketogenesis in the liver. The δ cells consist 
of less than 10% of islet cells (83), and these cells secrete somatostatin. Somatostatin 
receptors are expressed on both α and β cells, and the somatostatin receptor 2 (SSTR2) 
is the functionally dominant form of the receptor in humans and mice (84). The SSTR2 is 
a Gi-coupled G protein coupled-receptor (GPCR) that inhibits adenylyl cyclase activity 
and cyclic AMP (cAMP) generation. Activation of SSTR induces hyperpolarization of 
cells and thus suppression of glucagon and insulin secretion (84). In response to 
elevated blood glucose levels, insulin and somatostatin levels rise.  Both insulin and 
somatostatin act on α cells to lower cAMP production and suppress glucagon secretion 
(85). Precisely how exactly these cells communicate in vivo remain to be completely 
understood.  
Other endocrine cells in islet include the polypeptide-producing PP cells and 
ghrelin-producing ε cells, which consist of less than 5% and 1% of islet cells, 
respectively (83). The function of these cells is less understood in terms of regulation of 
β cell function. Ghrelin is known to inhibit insulin secretion (86) and also has activity as a 
“hunger hormone” by acting on hypothalamus (87).  
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The development and differentiation of the endocrine cell in the islet has been 
extensively studied using a variety of knockout mouse models. Neurogenin-3 (Ngn3) 
serves as the key marker for the endocrine pancreatic progenitor cell and is first 
expressed in the pancreatic buds around E9.5 in the mouse.  Ngn3 expression is crucial 
for commitment to the endocrine cell lineage (88). Lineage-tracing studies have shown 
that Ngn3 positive cells serve as the precursor for all five endocrine cell subtypes (89). 
During this differentiation process, Ngn3 coordinates with the pancreatic and duodenal 
homeobox 1 (Pdx-1) transcription factor in a time specific manner (90). Additional 
research is needed to define the differentiation pathway to establish β cells from stem 
cells, elucidate transcriptional micro RNA and epigenetic factors that regulate β cell 
differentiation, establish signature of β cell “specific” gene expression, and delineate 
pathological changes in these areas that are causative or associated with diabetes.    
  
 
1.1.4 Mechanisms of insulin secretion 
A striking feature of the pancreatic β cell is its ability to monitor blood glucose on 
a minute to minute basis and to precisely match ambient glucose levels with regulated 
levels of insulin secretion to maintain euglycemia in the range of 3.9 – 5.5 mM.  To 
accomplish this task, the β cell relies on several unique pathways to monitor blood 
glucose concentrations and regulate insulin release (Fig. 1) (91). Glucose transporters 
(Glut), mitochondrial ATP synthesis, closure of ATP-sensitive K+ channels (KATP 
channels), Ca2+ influx from plasma membrane channels are all involved in this process 
and any disruption of any of these steps will lead to impaired insulin secretion. 
 β cells are electrically excitable, and they possess a variety of channels that 
modulate membrane potential (Vm) and Ca2+ influx. In response to an increase in 
plasma glucose, glucose first enters the β cell through Glut transporters.  Glucose 
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metabolism in the mitochondria leads to an increase in the ATP/ADP ratio (92). The 
main regulators of β cell electrical activity are the KATP channels. Under low glucose 
conditions, KATP channels are open to induce a K+ outward current to maintain plasma 
membrane hyperpolarization at ~ -70mV (91). In β cells at rest, the constitutive 
hyperpolarizing K+ efflux and the constitutive unknown background-depolarizing current 
are balanced to achieve the resting membrane potential. Under high glucose 
concentrations, an increase in the ATP/ADP ratio leads to KATP channel closure. The 
reduced hyperpolarizing current by the closure of KATP channels will be exceeded by 
background-depolarizing current to depolarize cells. The mechanism that induces this 
background-depolarizing current and whether that current is modulated by glucose per 
se are not well understood. It has been speculated that forward operation of the 
Na+/Ca2+ exchanger (93), Cl- efflux, or Na+ (94) or Ca2+ influx (95) through unknown 
channels are involved in this background-depolarizing current. This depolarization 
activates voltage-dependent Ca2+ channels (VDCCs), and the resulting Ca2+ influx 
triggers exocytosis of insulin vesicles and insulin secretion. Action potentials generated 
by this process are primarily result from Ca2+ influx in mice.  However, a Na+ current is 
also involved in human and rat β cells. 
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Figure 1. Molecular mechanisms of insulin secretion in the pancreatic β cells. 
(1) Glucose uptake occurs through the Glut glucose transporters, and glucose is 
metabolized to produce adenosine triphosphate (ATP). (2) The increase in ATP will 
close ATP-sensitive K+ channels (KATP) to trigger depolarization. (3) VDCCs open and 
Ca2+ influx occurs. (4) Ca2+ induces exocytosis of insulin vesicles.  The colored circles 
indicate glucose (pink), ATP (orange), K+ (purple), Ca+ (green), and insulin (blue). 
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1.1.5 ER stress and various stresses are present in diabetes 
During the evolution of both Type 1 and 2 diabetes, β cells are exposed to 
multiple stressors, including elevated levels of pro-inflammatory cytokines, glucose, and 
free fatty acids, hypoxia, and misfolded protein accumulation, leading to activation of a 
number cell intrinsic stress pathways such as oxidative and ER stress, and maladaptive 
changes in autophagy (96). These multiple stressors activate the stress pathways and 
contribute to β cell dysfunction and death and may contribute to β cell de-differentiation 
(97,98).  
Pancreatic β cells possess a highly developed endoplasmic reticulum in order to 
meet the high demands of insulin protein synthesis and secretion.  As a result, β cells 
are particularly susceptible to endoplasmic reticulum stress, which has been a focus of 
my thesis studies.  Specifically, my studies have investigated novel pathways that lead 
to dysregulation of ER Ca2+ homeostasis and how loss of ER Ca2+ leads to ER stress.   
The endoplasmic reticulum (ER) is an organelle found in all eukaryotic cells. The 
structure of ER is a continuous membranous network surrounding a series of sacs 
known as cisternae. The ER is divided into a ribosome-rich “rough” ER and a ribosome-
free “smooth” ER (99). Rough ER is abundant in cells that secrete large amount of 
proteins including insulin-producing pancreatic β cells (100). The ER membrane 
constitutes more than half of the total cellular membrane structure and it functions as the 
site of (a) synthesis, folding, modification and transport of proteins; (b) quality control for 
newly synthesized proteins; and (c) Ca2+ storage that plays a role both in the 
maintenance of normal ER functions and as a source of released Ca2+ that serves a 
cellular second messenger to regulate a variety of signaling pathways (101). Under 
normal conditions, Ca2+- dependent chaperone proteins assist in the folding of proteins.   
These folded proteins are transported to the Golgi apparatus for further maturation.  
Proteins that are improperly folded or “misfolded” are removed by a quality control 
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system called ER-associated degradation (ERAD) (102). ERAD involves protein 
ubiquitination that promotes retro-translocation from the ER to the cytosol, where 
misfolded proteins undergo proteasome-induced degradation. On the contrary to the 
effect favor to help the ER functions, once the demand of the protein synthesis 
surpasses the ER capacity of protein folding and quality control, misfolded proteins can 
accumulate within the ER lumen, leading to ER stress.  Accumulation of misfolded 
proteins triggers an adaptive cascade aimed at restoring normal ER function, which is 
referred to as the unfolded-protein response (UPR) (103,104). This adaptive response 
induces downregulation of overall protein translation, while chaperone proteins and 
ERAD-associated proteins are preferentially translated (103,105). If the UPR’s adaptive 
response cannot restore normal ER function, prolonged activation of UPR will eventually 
initiate cellular apoptosis (106). ER stress can impact a variety of different cell types and 
contributes to a number of disease pathologies, including cardiac and 
neurodegenerative diseases as well as diabetes.  
The molecular mechanisms of the UPR have been well studied (Fig. 2). There 
are three main branches of this signaling pathway and the initiation of each branch is 
regulated by three different ER stress sensors located on ER membrane.  These include 
the inositol-requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and PKR-
like ER kinase (PERK). Upon binding of unfolded proteins to these three sensor proteins, 
the dissociation of Bip protein from the sensor proteins occurs. Although the exact 
mechanisms of how Bip protein attaches and dissociate from each sensor is s unknown 
(107), this is thought to initiate the unfolded proteins response, UPR. In addition, the 
direct interaction of misfolded proteins with the luminal portion of IRE1 has also been 
shown to activate the UPR (108). Following Bip dissociation, IRE1 undergoes 
oligomerization and autophosphorylation, initiating this branch of the UPR. IRE1 has 
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dual functions as endoribonulease and kinase. To reduce the overall protein load, IRE1 
degrades a large number of mRNAs (109), while X-box binding protein 1 (XBP1) mRNA 
is spliced by IRE1, allowing translation of XBP1 protein. XBP1 is a transcription factor 
that increases the expression of genes related to both UPR and ERAD (110). Included in 
these targets are chaperone proteins, which play a central role in the folding of client 
proteins in the ER, ATF6 that is the second of these ER stress sensors with which 
activation of this branch is initiated by translocation of ATF6 to the Golgi apparatus 
under ER stress conditions. ATF6 is subsequently cleaved to give rise to a cytosolic 
fragment known as p50 that forms either a homodimer or heterodimer with XBP1 to 
promote transcription of additional UPR effectors including ATF6 itself (105,111). Finally, 
the PERK branch of the UPR is thought to be initiated BiP dissociation, followed by the 
oligomerization and autophosphorylation of PERK. Phosphorylated PERK 
phosphorylates eukaryotic initiation factor eIF2α to inhibit activity of this translation factor. 
This results in a global translational block to prevent further accumulation of misfolded 
protein. However, selective translations of transcription factor, such as transcription 
factor 4 (ATF4), will be taken place.  ATF4 expression is repressed in the unstressed 
state, but the phosphorylation of eIF2 under ER stress will initiate the translation of ATF4 
(112).  
In contrast to this adaptive effect, prolonged activation of the UPR results in 
apoptosis. Key transcriptional regulators in this pathway, ATF4, ATF6, and XBP1, also 
initiate transcription of genes encoding proapoptotic proteins, such as C/EBP 
homologous protein (CHOP). The function of CHOP is to decrease expression of the 
anti-apoptotic protein Bcl-2 and activate the pro-apoptic factor Bcl-2-interacting mediator 
of cell death (Bim) (113,114). Similarly, phosphorylated IRE1 can activate the apoptotic 
pathway via activation of c-Jun N-terminal kinase (JNK), which leads to inactivation of 
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anti-apoptotic Bcl-2 and activation of pro-apoptotic Bim (115). As a consequence of Bcl-
2 inhibition, the pro-apoptotic proteins Bax and Bak undergo oligomerization that 
permeabilizes the outer mitochondrial membrane, resulting in Ca2+ overload in the 
mitochondria. Cytochrome C is subsequently released from mitochondria, leading the 
initiation of caspase-mediated cell death pathways.  
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Figure 2. Unfolded protein response and ER Ca2+ 
Under ER stress conditions, ER Ca2+ homeostasis is disrupted and Ca2+ -dependent 
chaperone proteins cannot meet the excess demand for protein folding leading to the 
accumulation of unfolded proteins. As a result, dissociation of chaperone protein Bip 
from the ER stress sensor proteins PERK, ATF6, and IRE1 occur. This triggers the 
activation of unfolded protein response (UPR). Prolonged activation of the UPR 
eventually causes apoptosis.  
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1.2 ER Ca2+ dynamics and diseases  
A focus of my thesis work has been on the identification of pathways that 
maintain ER Ca2+ levels.  Cells possess a variety of systems and safeguards to maintain 
distinct Ca2+ stores and concentration gradients that are crucial for cellular function and 
survival.  Specifically, a distinct Ca2+ gradient exists between the membranes of the 
extracellular space, cytosol, and intracellular organelles. These gradients allow cells to 
maintain organelle function, while also contributing to spatiotemporal calcium signaling.  
Disruption of gradients can contribute to disease pathophysiology.  In the pancreatic β 
cell, disruption of these gradients leads to impaired insulin production and secretion as 
well as apoptosis.  Under resting conditions, intracellular Ca2+ is maintained at a level at 
least four orders of magnitude lower than extracellular Ca2+. In addition, free ER Ca2+ is 
maintained at approximately two orders of magnitude higher than the intracellular Ca2+ 
(116), while mitochondrial Ca2+ levels are comparable to that of intracellular Ca2+ 
(117,118). The rank order of Ca2+ concentration in each compartment at rest is 
summarized as: Extracellular Ca2+ (~2 mM)> ER Ca2+ (~100 µM) > Mitochondria Ca2+ 
(~200 nM) ≥ Intracellular Ca2+ (~100 nM).   
Meticulous coordination of ion transporters including channels on the plasma 
and organelle membranes establish these Ca2+ gradients. On the β cell plasma 
membrane, the Na+/Ca2+ exchanger (NCX) and the plasma membrane Ca2+ ATPase 
(PMCA) transfer excess intracellular Ca2+ into the extracellular space to maintain low 
cytosolic calcium levels.   Among the many cellular organelles, the ER is the largest  
Ca2+ store. As is the case for NCX and PMCA, the Sarco/endoplasmic reticulum Ca2+ 
ATPase (SERCA) also works to eliminate excess intracellular Ca2+ by pumping calcium 
into the ER. This process is regulated by SERCA, PMCA, and NCX and is called Ca2+ 
clearance. The process of calcium clearance is particularly important following a β cell 
secretory burst.  Mathematical modeling based on the experiments performed in 
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dispersed mouse β cells suggests 50-64% of intracellular Ca2+ transients induced by 
KCl, which causes depolarization, are removed by the SERCA pump (119). After that, 
21-30% of the excess Ca2+ will be cleared by NCX when intracellular Ca2+ is high ~>1 
µM, and  21-27% of Ca2+ will be removed by PMCA when intracellular Ca2+ is low at 
around ~0.5 µM (119). Other factors such as the mitochondrial calcium uniporter (MCU) 
and the gap junction channels, connexin 36 (Cx36), are anticipated to play a role, but 
have been less well studied (91).   
Like the PMCA pump, the SERCA pump uses ATP to transport Ca2+ against the 
steep calcium concentration gradient between the cytosol and ER. In contrast to 
SERCA, inositol 1,4,5-trisphosphate and ryanodine receptors (IP3R and RyR) are Ca2+ 
releasing channels that passively release Ca2+ from the ER lumen into the cytosol. 
Another important organelle for cellular Ca2+ homeostasis is the mitochondria, which has 
been less characterized in β cells, but may function as a transient Ca2+ buffer. The MCU 
and leucine- zipper EF-hand-containing transmembrane protein 1 (LETM1) are localized 
to the mitochondrial inner membrane and drive Ca2+ uptake into mitochondria (120).  In 
contrast, Na+/K+/Ca2+-exchange protein 6 (NCLX) is the transporter that releases Ca2+ 
from mitochondria into the cytosol (96,121). 
 
1.2.1 The role of the SERCA in health and disease  
ER Ca2+ levels represent the balance of calcium uptake via the SERCA pump 
and calcium release via the RyR and the IP3R. SERCA is an active transporter that 
senses and pumps excess intracellular Ca2+ into the ER. Since this process is also ATP 
dependent, SERCA functions as a metabolic sensor (122,123).  
SERCA protein is encoded by three distinct genes:  ATP2A1, ATP2A2, ATP2A3 
(SERCA1, SERCA2 and SERCA3 respectively). There is a high level of conservation 
among the different isoforms, with more than 75% structural homology observed 
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between the isoforms (124). Each gene encodes 2-6 alternatively spliced transcripts. 
SERCA1 is expressed exclusively in fast-twitch skeletal muscle. SERCA2 splice variants 
are expressed in a tissue-specific manner. SERCA2a is expressed mainly in cardiac and 
slow-twitch skeletal muscle, whereas SERCA2b is ubiquitously expressed. SERCA3 is 
expressed only in particular tissues including β cells and is usually co-expressed with 
SERCA2b (125).  
Acquired SERCA deficiencies have been implicated in a variety of diseases. 
Darier-White disease is an inherited skin disease that arises as a result of SERCA2 
haploinsufficiency and is characterized by the loss of keratinocyte adhesion, which is 
termed acantholysis, occurring as a result of disruption of ER Ca2+ levels in the 
keratinocytes (126,127). Persons with Darier-White disease also have higher rates of 
epilepsy and depression (126,128). Whether these individuals are more suspectible to 
metabolic disease has not been tested. SERCA2a expression and Ca2+ affinity are 
decreased in heart failure (129) and have been associated with cardiac myopathies 
(130). Moreover, cardiac function was improved by overexpression of SERCA2a in a rat 
model of heart failure (131,132).  In addition, the Ca2+ affinity of SERCA2 was increased 
by suppression of the phosphorylated form of the membrane-localized inhibitory protein, 
phospholamban in a hamster model of heart failure (133). Also, ablation of 
phospholamban in cardiomyopathic mice (134) has been shown to improve contractility 
in heart failure (135). Therefore, improving SERCA function may represent a potential 
therapeutic strategy for a variety of diseases. 
The dominant form of SERCA in the pancreatic β-cells is SERCA2b (54). The 
structural difference between SERCA2a and SERCA2b is limited to the COOH-terminal 
(C-terminal) of each protein.  SERCA2b contains a unique 49-amino acid C-terminal 
extension that creates an 11th transmembrane α-helix in this protein with the C-terminus 
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tail projecting into the lumen of the ER. This structural difference grants this isoform the 
highest affinity to Ca2+ (2b>2a>3) and the lower ATPase turnover rate (3>2a>2b) (136).  
Accumulating evidence suggests that altered SERCA expression and activity 
contributes to the pathophysiology of diabetes, leading to both impaired insulin secretion 
and β cell death (137-139). The contribution of SERCA to Ca2+ clearance following 
glucose exposure has been experimentally assessed using dispersed mouse islet β 
cells. Chen et al. demonstrated that about two-thirds of the depolarization-induced Ca2+ 
influx was removed by SERCA (119). This suggests that SERCA can indirectly regulate 
insulin secretion by controlling intracellular Ca2+. Moreover, SERCA may play a 
significant role in the amplitude and the downward phase of the glucose-induced Ca2+ 
oscillations (GICOs) that additionally regulate insulin secretion. Functional studies of 
SERCA have been enabled due by the SERCA inhibitor, thapsigargin (TG). Inhibition of 
SERCA leaves only Ca2+ releasing channels, RyR and IP3R functional, which results in 
the depletion of ER Ca2+ across the concentration gradient. Prolonged TG treatment 
leads to ER stress and apoptosis (140), again emphasizing that ER Ca2+ is required for 
cell survival and function. 
 
1.2.2 The role of the Ryanodine Receptor in health and disease 
Whereas SERCA functions to pump Ca2+ into ER to maintain ER Ca2+ levels, ER 
Ca2+ releasing channels, IP3R and RyR, are both expressed in the β-cell (141-143) and 
coordinately function to maintain ER Ca2+ homeostasis and ER function. For instance, 
excess ER Ca2+ is released by IP3R and RyR to maintain Ca2+ balance and 
homeostasis. In addition, acute release from these channels also contributes to a variety 
of intracellular signaling pathways.  Mammalian RyR has three different isoforms.  RyR1 
is mainly expressed in skeletal muscles and is localized in junctional terminals between 
the plasma membrane and sarcoplasmic reticulum (SR), while RyR2 is predominantly 
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expressed in cardiac muscles.  RyR3 was found to be ubiquitously expressed (144-146). 
Functional RyRs consist of homotetramers (147). RyRs are also expressed in other 
nonmamalian vertebrates such as birds and fish with the isoforms RyRa and RyRb 
(148). Furthermore, RyR expression has been found in other metazoans, including C. 
elegans and Drosophila melanogaster (149,150). 
RyRs are associated with many different human diseases, with the majority of 
diseases arising as a result of alterations in channel gating properties (147). Diseases 
caused by mutations in the RyR1 gene include malignant hyperthermia, leading to 
increased sensitivity to inhalation anesthetics that can lead to sustained muscle 
contraction (151). RyR1 mutations may also lead to exertional rhabdomyolysis, 
characterized by the breakdown of striated muscles in response to heat or exercise 
(152); central core disease, which is a mild congenital myopathy characterized by 
hypotonia and muscle weakness of the upper legs and hips (153); and multiminicore 
disease that is autosomal recessive myopathy with degeneration of muscle fibers 
causing weak limb muscles (154).  
Diseases caused by mutations in the RyR2 include catecholaminergic 
polymorphic ventricular tachycardia (CPVT), which is characterized by stress- or 
exercise-induced ventricular tachycardia that can lead to sudden death (155). Calstabin1 
and 2 (also called FKBP12 and FKBP12.6) are expressed in most tissues and function 
to bind and stabilize the RyR1 and RyR2 in the closed state (156-159). Mutation of the 
V2461 in RyR1 abolished calstabin1 binding (160).  Inhibition or loss of calstabin1 
binding greatly increased the open probability and open duration for the channel 
(161,162) Calstabin1 displacement in skeletal muscle alters EC coupling between RyR1 
and Cav1.1 (163), whereas loss of calstabin1 in cardiac muscle results in 
cardiomyopathy as well as developmental congenital heart defects (164). 
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In vitro and animal studies have shown that the CPVT associated mutation in 
RyR2 results in Ca2+ leak through the receptor by lowering affinity for FKBP12.6, also 
known as calstabin2 (165) or by increasing sensitivity to β-adrenergic receptors to 
induce prolonged Ca2+ transients (166). In CPVT, protein kinase A (PKA) and 
Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation of RyR2 has 
been also been documented to change RyR2 function (167,168).  Thus, in persons with 
CPVT, β-adrenergic stress and exercise induced PKA phosphorylation along with a 
leaky RyR2 are thought to contribute to arrhythmias. Mutations in RyR2 are also 
responsible for arrhythmogenic right ventricular dysplasia type 2 (ARDV2), which is an 
autosomal dominant disease characterized by degeneration of myocardium, leading to 
ventricular arrhythmias and sudden death (169). The mutation associated with ARDV2 
also leads to dysfunction in RyR2 via Ca2+ leak from myocardial SR (170).  In contrast to 
RyR1 and RyR2, RyR3 is the isoform that has been least studied. One study suggested 
that upregulation of RyR3 in cortical neurons may play a protective role in Alzheimer’s 
disease (171). 
 The RyRs exhibit approximately 65% sequence homology, but each RyR isoform 
has different modes of regulation. RyRs form a macromolecular complex with a variety 
of proteins including L-type voltage dependent channels, Cav1.1/Cav1.2, PKA, 
Calstabin1 and 2, CaM, CaMKII and calsequestrin. Therefore, receptor function can be 
modulated by proteins within these larger complexes. The regulation of these complexes 
have been extensively studied in electrical – contraction (EC) coupling, which is 
regulated by Ca2+ release from SR in skeletal and cardiac muscles. In skeletal muscle, 
multiple regions of Cav1.1 and RyR1 physically interact to regulate EC coupling (172-
174). Due to this physical interaction rather than Ca2+ induced activation, EC coupling in 
skeletal muscle is prolonged even in the absence of extracellular Ca2+ (175,176). In 
contrast, RyR2 in cardiac muscle is activated by Ca2+ influx through Cav1.2, and this 
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mode of RyR2-mediated ER Ca2+ release is called Ca2+ induced Ca2+ release (CICR) 
(177). Ca2+ influx through Cav1.2 does not directly induce muscle contraction, but much 
larger Ca2+ release from RyR2 by CICR mediates muscle contraction (178).  
Single channel studies have shown that RyRs exhibit biphasic activation by Ca2+. 
Low intracellular Ca2+ concentrations (<0.01-20µM) can activate RyRs, whereas higher 
intracellular Ca2+ concentration (~100 µM – 10 mM) can inhibit RyRs (179). In addition to 
the activation from the cytosolic side, single channel recordings have shown that Ca2+ 
can activate RyR from ER luminal side in response to increased ER Ca2+ (180,181). This 
is referred to as store overload induced Ca2+ release (SOICR). Structural studies 
indicate that highly electronegative luminal loop domains are responsible for RyR 
activation in SOICR (182). Spontaneous SOICR in cardiac cells are capable of inducing 
Ca2+ waves and delayed after depolarizations resulting in ventricular tachyarrhythmias 
(183). This is caused by the abnormal RyR2 activation due to RyR2 mutations 
associated with CPVT, which lowered the threshold of the SOICR (22 23).  
  Ca2+ may also regulate RyR function through calmodulin (CaM), which is a 
ubiquitously expressed Ca2+ binding protein. CaM contains four EF-hand Ca2+ binding 
sites.  CaM is known to bind to each RyR monomer (184) and also plays a role in 
regulating Cav1.1 and Cav1.2 (185-187). Studies have shown that CaM is capable of 
suppressing RyR2 function by elevating the threshold of intracellular Ca2+ for RyR2 
activation in cardiac muscle (188). Decreased CaM binding affinity for RyR2 was 
observed in the mouse model of CPVT that has a RyR2 R2474S mutation, resulting in 
lethal arrhythmias (189). 
 Post-translational modification of RyRs also regulate their activity.  RyRs possess 
multiple phosphorylation sites in the cytoplasmic domains including sites for 
phosphorylation by PKA, CaMKII and cGMP-dependent kinase (PKG) (190-193). During 
the “fight or flight” stress response, the sympathetic nervous system (SNS) is activated 
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resulting in increased calcium transients and faster muscle contractions (194). This 
pathway involves β adrenergic receptor and PKA activation leading to RyR 
phosphorylation and altered gating properties (167,195). In addition 
hyperphosphorylation of RyR2 serine residues at the calstabin 2 binding site and 
concomitant dissociation of calstabins and resulting RyR2-mediated Ca2+ leak are 
suggested to play a role in both heart failure and during severe stress (168). CaMKII 
dependent phosphorylation of RyR2 is also suggested to enhance SR Ca2+ leak and 
decrease of SR Ca2+ load in heart failure (196).  
In addition, alterations in redox state of RyRs can both activate (197,198) or 
inhibit channels (199). Cysteines in RyR1 and RyR2 are covalently bound by NO (S-
nitrosylation) (200), and high level of ROS/RNS can irreversibly modify RyR function 
(201). For example, S-nitrosylation of Cys3635 in RyR1 has been found to reverse the 
CaM mediated inhibition leading to channel activation (202), which can facilitate muscle 
contraction (203). S-nitrosylation of Cys3635 in RyR1 has also been observed in 
muscular dystrophy leading to elevated SR Ca2+ leak (204). On the contrary, RyR2 
cannot S-nitrosylated by NO, and RyR2 has to go through S-nitrosoglutathione, 
endogenous NO carriers and donors, to undergo S-nitrosylation (205). In addition to 
Ca2+, Mg2+ and ATP also regulate RyRs. Mg2+ is suggested to reduce the open 
probability of RyR by competing with Ca2+ for the Ca2+ activation site (206,207). ATP 
may also activate RyRs in absence of Ca2+, but will have a maximum effect in the 
presence of Ca2+ (206,208). 
 While the association of abnormal RyR function has been well-described in heart 
disease, how RyRs function and dysfunction affects the pancreatic β cell and the 
development of diabetes is not well understood. Since only Cav1.2 and Cav1.3 are 
detected in rodent and human β cells (209), depolarization induced RyR activation 
mediated by Cav1.1 does not exist in β cells. Rather, CICR mediated by Cav1.2 and 
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RyR2 is thought to be the major form of RyR regulation in the β cell. Santulli et al. 
reported the metabolic phenotype of mice with RyR2 mutation in R2474S and N2386I 
and, humans with CPVT mutation in RyR2.  Collectively, these mutations induced 
dysregulated ER Ca2+ release through RyRs and led to impaired insulin secretion (210). 
This group found that these mutations caused dissociation of calstabin2 from RyR2, and 
thus pharmacologically stabilizing interactions between calstabin2 and RyR2 by S107. 
S107 functioned to enhance binding of calstabin2 to RyR2, and therefore partially 
rescued the ER Ca2+ release through RyR and abnormal insulin secretion (210). 
Furthermore, it was found that Dantrolene, which is an inhibitor of RyR1 and RyR3, 
reduced cell death under TG-induced ER stress in Min6 β cells (211). Similarly, Lu et al. 
reported that treating with Dantrolene protected from apoptosis induced by TG using 
INS-1 cells where the WFS1 gene was knocked down (212). However, these studies 
were performed by inducing ER Ca2+ loss through SERCA inhibition, and they provide 
limited insight into how physiological stressors may change RyR function and ER Ca 
dyanamics. Thus, a goal of my project has been to study β cell RyR function in the 
context of pro-inflammatory stress and ER stress.   
 
1.2.3 The role of the IP3R in health and disease 
 Inositol 1,4,5-triphosphate receptors (IP3R) are expressed in most eukaryotes 
and play an important role in regulating ER calcium release. In contrast to RyRs, 
functional IP3Rs consist of tetramers assembled by either identical subunits or by 
mixture of the three subtypes IP3R1, IP3R2 and IP3R3 and each subtype has many 
splice variants (213-215) . IP3R are activated by IP3, which is produced by the Gαq G-
protein coupled receptor (GPCR) pathway and acts to stimulate Ca2+ release from the 
major IP3-sensitive Ca2+ stores, including the nucleus, ER (216), Golgi, and likely the 
secretory vesicles.  (217-219).  In response to various endogenous ligands, Gαq subunit 
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activates phospholipase C (PLC) to catalyze hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) to produce IP3 and diacyl glycerol (220). IP3 interacts with α- and β- 
domains of IP3R, pulling the two domains closer (221). IP3Rs play a central role in the 
propagation of Ca2+ waves, which is regenerative increased intracellular Ca2+. The 
increased intracellular Ca2+ is sensed by RyR or IP3R to induce ER Ca2+ release called 
Ca2+-induced Ca2+ release (CICR) (222). The Ca2+ wave can propagate throughout the 
entire cell or even between cells to induce various biological effects. This was first 
observed during fertilization, which was found to occur through an IP3R dependent 
process (223). IP3 can hierarchically induce different forms of IP3R activation, ranging 
from activation of a single IP3R, to activation of a cluster of several IP3Rs, and finally to 
activation of all cellular IP3R to induce a Ca2+ wave (224,225). Activation of IP3Rs 
requires both IP3R and intracellular Ca2+ (226,227).  However, whether each subunit of 
IP3R tetramer requires the occupancy of an IP3 molecule is still not known. In parallel to 
RyRs, the effects of Ca2+ are biphasic.  Modest increases in intracellular Ca2+ (~µM) 
enhance IP3 responses, whereas higher intracellular Ca2+ (µM-mM) can inhibit the IP3R 
response (226,228). Experiments performed using purified IP3Rs reconstructed in a lipid 
bilayer have confirmed the activation of IP3R by Ca2+, but not its inhibition (229,230).  
These results suggest that proteins might be responsible for inhibition mediated by high 
Ca2+ levels, rather than direct Ca2+ binding to the IP3R (231). CaM has been suggested 
to be such a protein responsible for this effect based on the presence of CaM binding 
domains in the IP3R.  However, this as yet to be proven (232). Other IP3R regulators 
include intracellular ATP (233) and cyclic AMP (cAMP), which is an intermediate product 
of Gαs-GPCR pathway.  Cyclic AMP can regulate IP3R through multiple mechanisms.  
First, cAMP induces production of IP3 through EPAC-mediated activation of PLC and IP3 
production (232,234). In addition, all three IP3R subtypes are phosphorylated by PKA, 
which is in turn activated by cAMP.  Thus, cAMP-mediated phosphorylation potentiates 
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IP3-induced Ca2+ release by IP3R1 and IP3R2 (235). Finally, high cAMP concentrations 
induce a direct interaction between cAMP and IP3Rs to sensitize their activities (236).  
Structurally speaking, very little is known about how Ca2+ regulates IP3R. Unlike 
the RyR, there are no EF Ca2+-binding motifs within IP3R.  However, there are clusters of 
negatively charged residues that could serve as Ca2+ binding sites (237). A study that 
mutates the Glu2100 residue to a aspartic acid or glutamine reduced the Ca2+ sensitivity 
of the IP3R by 5 – 10 fold, suggesting might serve as the site of IP3R regulation by Ca2+ 
(238,239). Two studies have suggested that an increased ER Ca2+ load increased the 
sensitivity of IP3R to IP3 (240,241). Thus, regulation of the IP3R by luminal ER Ca2+ 
regulation is possible, but has yet to be definitively proven. A high-affinity Ca2+-binding 
site exists within the luminal loop of the transmembrane domain 5 and 6 contains 
conserved acidic residues that could mediate luminal Ca2+ regulation (242).  
While altered IP3R function has been suggested in a variety of diseases, 
including cardiac and neurodegenerative diseases, overall this topic has been less 
studied than RyR dysfunction. The expression level of IP3Rs have been shown to be 
increased in cardiac hypertrophy, atrial fibrillation and hypertension (243-245). Among 
the three subtypes, IP3R1 is the dominant form in brain (214), and impaired IP3R1 
function has been associated with Huntington’s disease (246) and Alzheimer’s disease 
(247).  Mutations in the gene encoding IP3R1 leads to spinocerebellar ataxia, a disorder 
characterized by progressive loss of muscle coordination (248,249). Compared to 
studies investigating RyR dysfunction, even fewer number of studies have linked IP3R 
dysfunction to diabetes pathophysiology.  So far, it has been shown that TG induced cell 
death was partially protected by inhibiting IP3Rs in the Min6 β cell line (211).  Further 
investigation will be necessary to fully define a role for the IP3R in diabetes 
pathophysiology. 
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1.2.4. ER Ca2+ dynamics and cellular excitability 
As with other secretory cells, pancreatic β cells are electrically excitable and 
capable of firing action potentials. Action potentials exist in both metazoan and plant 
cells, and they serve as a means to facilitate rapid communication between cells or 
tissues.  In this regard, action potentials are used in β cells within islets to achieve rapid 
and synchronous insulin secretion, thus minimizing the time gap between glucose 
sensing and integrated insulin secretion at a whole-islet level (250).  
Action potentials in β cells are generated mostly via Ca2+ influx through the 
activation of voltage-gated Ca2+ channels (47). Unlike mouse β cells, Na+ current also 
contributes to action potentials in human β cells (47,251). The pattern of action potential 
firing can increase the toxi Hyperexcitation is described as a state of excess action 
potential generation and has been shown to contribute to neurological disorders such as 
Alzheimer’s disease (252,253), Parkinson’s disease (254), epilepsy (255), and 
neuropathic pain (256). Hyperexcitation is also known to be toxic to cells and is referred 
to by the term “excitotoxicity”. In neurons, cells undergo excitotoxicity due to 
overstimulation by excitatory amino acids, such as glutamate, resulting in excessive 
depolarization and action potential generation leading to cell death (257). In this process, 
glutamate receptors and Ca2+ channels induce Ca2+ overload, which triggers 
mitochondrial production of reactive oxygen species and induction of apoptosis 
(257,258). Another mechanism that induce neural excitotoxicity is hypoglycemia, 
because glucose is required for cells to take up a glutamate in the brain (259). In 
addition to neuronal diseases, hyperexcitability of cells may also contribute to cardiac 
arrhythmias (260,261). 
Limited studies have been performed to investigate the relationship between β 
cell hyperexcitability and diabetes. In this regard, studies have investigated the 
relationship between sulfonylureas, which block KATP channels to induce β depolarization 
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and hyperexcitability. Clinical studies have suggested that sulfonylureas may hasten β 
cell failure (262), but the mechanisms underlying loss of insulin secretion by 
sulfonylureas remains poorly understood and is controversial.  However, a leading 
hypothesis is that chronic hyperexcitation of β cells (263) eventually causes excitotoxic 
response, leading to loss of β cell function (264-266) and eventual cell death (267) and. 
Chronic glucotoxicity has been similarly implicated.  In fact, in the presence of high 
glucose for extended periods, glucose-stimulated insulin secretion was impaired and 
islet insulin content was depleted in rat and human islets (268-270). This was prevented 
by co-treatment with the KATP channel opener diazoxide, as opening of KATP channel 
resulted in hyperpolarization, which inhibits Ca2+ influx from Cav (271-273). Furthermore, 
gain-of-function mutation of KATP channels, which increases excitability of β cells, caused 
high insulin secretion independent of blood glucose level and caused congenital 
hyperinsulinism of infancy (274). The loss-of-function mutation of KATP channels, which 
decreases excitability of β cells, caused neonatal diabetes mellitus (275). Therefore, 
KATP channels plays a critical roles of the excitability of β cells in health and disease. The 
exact molecular mechanisms for excitotoxicity, including the channels responsible for 
this phenomenon are yet to be found.  
 
1.2.5. Ca2+ oscillation and ER Ca2+ dynamics 
In response to elevated blood glucose levels, β-cells begin to oscillate 
intracellular Ca2+ levels synchronously in waves that propagate throughout the entire 
islet, with a frequency ranging from one per second to minutes (250). This phenomenon 
is referred to as glucose-induced Ca2+ oscillations (GICOs) and result from 
synchronous oscillation of Vm leading to Ca2+ influx through voltage-gated Ca2+ channels 
(250,276). The synchrony of oscillations among all islet β-cells are due to gap junction 
channels, which are composed of connexin 36 (Cx36) and mediate diffusion of ions and 
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small molecules between neighboring β cells (277). Cx36 has high affinity for K+, and K+ 
influx from KATP channels is uniformly diffused throughout β cells establishing a uniform 
Vm that is a key basis for synchronous Ca2+ oscillation (278). Ca2+ triggers insulin 
exocytosis, GICOs are coupled with the rhythms of pulsatile insulin secretion. Therefore, 
studying the mechanisms of Ca2+ oscillation in health and in diabetes has clinical 
significance. The pulsatile insulin secretion in humans is crucial for maintaining normal 
glycemic control (279). Loss of oscillations are observed in diabetes, and disruptions in 
the normal patterns of oscillatory insulin secretion is thought to contribute to insulin 
secretion secondary to desensitization of receptors in peripheral tissues (280,281). 
Despite this background knowledge, the exact mechanisms of how GICOs occur and 
how loss of GICOs occurs under diabetic stress have not been fully established. Since it 
is known that ER Ca2+ dynamics modulates Vm and action potential firing, dysfunction of 
ER Ca2+ dynamics may contribute to impaired GICOs and altered insulin secretion in 
diabetes. 
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Chapter 2. Results 
2.1 ER stress and pro-inflammatory cytokine stress caused ER Ca2+ loss and 
disruption of glucose-induced Ca2+ oscillations.  
The pathophysiology of type 1 and type 2 diabetes involves both β cell ER stress 
and pro-inflammatory cytokine-induced β cell dysfunction. To define how these stress 
paradigms influenced the ER Ca2+ store, we treated with compounds and factors that 
induce ER stress and pro-inflammatory cytokine stress. INS-1 β cells were treated with 
300 nM Tunicamycin (TM) or 5 ng/ml Interleukin 1β combined with 25 mM high glucose 
(IL-1β + HG) in time-course experiments, and Ca2+ imaging was performed according to 
the schematic shown in Figure 3A.  Results revealed a time-dependent loss of ER Ca2+ 
with TM (Fig. 3B-C) and IL-1β + HG (Fig. 3D-E), where significant reductions in ER Ca2+ 
were observed within 6 hrs and further reductions were observed throughout the 24 hr 
exposure period. We next studied the effect of TM and IL-1β + HG on glucose-induced 
Ca2+ oscillations (GICOs) in islets from 8 wk old C57BL6/J mice. Under control 
conditions, regular intracellular Ca2+ oscillations were observed in response to glucose 
stimulation (Fig. 3F).  In contrast, both chemically induced ER stress and pro-
inflammatory cytokine stress abolished normal patterns of GICOs in mouse islets (Fig. 
3G).  To compare these findings in analogous mouse models, islets were isolated from 
6-8-wk old Akita mice, which harbor a spontaneous mutation in one allele of the INS2 
gene, resulting in impaired proinsulin folding and severe ER stress (282,283).  To 
recapitulate pro-inflammatory cytokine stress, islets were isolated from 9-12-wk old 
hyperglycemic db/db mice.  The strain has a mutated form of the leptin receptor resulting 
in hyperglycemia, obesity, and elevated systemic levels of pro-inflammatory cytokines 
(283,284).  Similar to results observed with ex vivo TM and IL-1β+HG treatment, GICOs 
were significantly impaired in islets isolated from Akita and db/db mice (Fig. 3H). Taken 
together, these data indicate that ER and pro-inflammatory stress are sufficient to disrupt 
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ER Ca2+ storage as well as GICOs in pancreatic β cells. 
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Figure 3. ER stress and pro-inflammatory cytokine-induced stress led to ER Ca2+ 
loss and disruption of glucose-induced Ca2+ oscillations  
Experiments were conducted using INS-1 cells (A-E) and mouse islets (F-G). (A) To 
estimate ER calcium storage, Calcium 6 was used to measure intracellular Ca2+ levels 
before and after application of 10 µM thapsigargin (TG), a potent inhibitor of SERCA 
pump activity.  (B) Representative traces for TG-induced Ca2+ release following 
treatment with 300 µM TM for indicated times. (C) TM-treatment led to a time-dependent 
reduction in ER Ca2+ levels; n = at least 7 replicates for each timepoint. (D) 
Representative traces for TG-induced Ca2+ release following treatment with 300 µM IL-
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1β + 25 mM glucose (ILHG) for indicated times. (E) ILHG-treatment led to a time-
dependent reduction in ER Ca2+ levels; n = at least 3 replicates for each time point. (F) 
Representative trace of changes in Fura2 intensity in islets from 8-12 week old wild-type 
C57BL6/J mice.  Islets were incubated in 5 mM glucose (G5) and then stimulated with 
G15 to induce GICOs; n = 3 biological replicates.  (G) Representative traces of GICOs in 
C57BL6/J islets under control conditions (Ctr) or following treatment with either 5 ng/ml 
IL-1β+25mM glucose for 24 hours (ILHG) or 10 µM TM for 48 hrs (TM); n = at least three 
biological replicates for each condition.  (H) Representative GICO traces in islets from 9-
12 week old db/db mice or 6-7 wk old Akita mice overlaid with GICOs of islets from 
C57BL6/J (Ctr) mice; n = at least three biological replicates for each genotype.  For (C) 
and (E); ***p ≤ 0.001 compared to Time 0.    
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2.2 RyR and IP3R function are differentially altered in response to ER and 
cytokine-induced stress 
Whereas previous studies have implicated β cell SERCA2 dysfunction in 
diabetes, a role for either RyR and IP3R dysfunction remains incompletely characterized 
(285). To define whether RyR and IP3R activity were altered in models of ER stress and 
pro-inflammatory stress, TM and IL-1β+HG-treated INS-1 β cells were loaded with the 
low-affinity Ca2+ indicator Mag-Fluo-4 AM, followed by membrane permeabilization with 
saponin.  As shown in Figure 2A, Mag-Fluo-4 AM was efficiently cleared from the 
cytosol, but remained sequestered within the ER, as indicated by overlap with RFP-
calnexin (Fig. 2A). Next, ATP was added to achieve steady state ER Ca2+ levels via 
SERCA activation.  Caffeine and IP3 were added to activate RyRs and IP3Rs, 
respectively, and dose-response curves were generated (Fig. 4B).  Interestingly, this 
analysis revealed that TM-induced ER stress primarily altered RyR responses (Fig. 4C), 
while IP3R function was minimally impacted by TM treatment (Fig 4D). In the short-term, 
TM increased the maximal RyR response, while reductions in RyR activity were 
observed with chronic TM treatment (Fig. 4C).  In contrast to TM treatment, RyR activity 
remained largely unaffected by IL-1β + HG  (Fig. 5A). Longer-term IL-1β + HG treatment 
reduced the EC50 of the IP3R response to agonist (Fig. 5B). Together, these results 
suggest that ER stress preferentially impacted RyR function, while chronic pro-
inflammatory stress preferentially impaired the IP3R response to agonist. 
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Figure 4. RyR function was preferentially altered by TM-induced ER stress 
(A) INS-1 cells were loaded with the low affinity Ca2+ indicator Mag-Fluo-4 AM (Green).  
Following plasma membrane permeabilization, Mag-Fluo-4 AM was retained in the ER 
as demonstrated by co-localization with calnexin (Red). To estimate RyR and IP3R 
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activity, calcium imaging was performed according to the schematic shown in Panel (B).  
First, 1.5 mM Mg-ATP was added to establish steady-state ER Ca2+ levels. Caffeine is 
an agonist for RyR, while IP3 is an agonist for IP3R. Caffeine or IP3 was applied in the 
indicated concentrations to generate-dose response curves of RyR and IP3R activation, 
respectively.  Decreases in Mag-Fluo-4 AM intensity were used to calculate relative ER 
Ca2+ release, and GraphPad Prism Software was used to fit data from IP3R and RyR 
functional assays to sigmoidal dose-response curves, which were analyzed by two-way 
ANOVA with Tukey-Kramer post-test.  (C) Upper panels show the dose-response curves 
for RyR activation by caffeine in INS-1 cells pre-treated with 300 nM TM or DMSO for 6, 
12, and 24 hrs.  Lower panels show the maximal response and 95% confidence intervals 
for each timepoint; n = at least 3 replicates for each timepoint in different caffeine 
concentration.  (D) Upper panels show the dose-response curves for IP3R activation by 
IP3 in INS-1 cells pre-treated with 300nM TM for 6, 12, and 24 hrs.  Lower panels show 
the maximal response and 95% confidence intervals; n = at least 3 replicates for each 
timepoint and IP3 concentration.  *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 compared to control 
conditions.  
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Figure 5. Pro-inflammatory cytokine stress impaired IP3R function 
(A) Dose-response curves for RyR activation by caffeine in INS-1 cells pre-treated with 5 
ng/mg IL + 25 mM glucose (ILHG) for 6, 12, and 24 hrs; n = at least 3 replicates for each 
timepoint and caffeine concentration.  (B) Dose-response curves for IP3R activation in 
INS-1 cells pre-treated with pretreated with ILHG for 6, 12, and 24 hrs. *p ≤ 0.05; **p ≤ 
0.01; ***p ≤ 0.001 compared to control conditions. Values shown are the LogEC50 for 
INS-1 cells analyzed under control conditions (top) and following ILHG-treatment 
(bottom). 
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2.3 Stress-mediated ER Ca2+ loss was reduced by RyR and IP3R inhibition 
To test whether RyR or IP3R inhibition was sufficient to prevent ER Ca2+ loss 
under diabetogenic stress conditions, we tested the effects of RyR antagonists, 
dantrolene and ryanodine (Ry), and the IP3R antagonist, xestospongin C (XeC) using 
INS-1 cells. Since Ry can activate RyR at low concentration (~ 1 nM) Ry 100 µM was 
used to inhibit RyR. Following tunicamycin treatment, there was a trend towards 
improved ER Ca2+ levels with dantrolene (Fig. 6A), while inhibition of RyR with Ry (Fig 
6B) significantly prevented ER Ca2+ loss compared to TM alone. Consistent with results 
from the functional assays, Ry was unable to block ER Ca2+ loss in response to IL-
1β+HG (Fig. 6D), whereas inhibition of IP3R with XeC partially rescued ER Ca2+ levels 
following IL-1β+HG treatment (Fig. 6C).  
ER stress and cytokines are known to induce β cell death (286), so we next 
tested whether modulation of ER Ca2+ loss via RyR or IP3R inhibition were sufficient to 
protect against β cell death.  TM-treatment resulted in a time-dependent increase in 
caspase 3- and 7 activity (Fig. 7A) and led to increased expression of cleaved-caspase 3 
protein (Fig. 7B).  Interestingly, cell death was partially abrogated by Ry co-treatment 
(Fig. 7A-B), suggesting that cell survival was improved through prevention of RyR-
mediated ER Ca2+ leak in response to TM-induced ER stress.  In contrast, despite an 
observed effect to partially restore ER Ca2+ levels (Fig. 5C), XeC was unable to reduce 
caspase activity in response to IL-1β+HG (Fig. 7C).    
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Figure 6. ER Ca2+ loss was prevented by blocking RyR under ER stress conditions 
and by IP3R blockade under pro-inflammatory cytokine stress conditions 
INS-1 cells were treated with 300nM TM for 24 hours with or without 1 µM Dantrolene 
(Dt) (A) or 100 µM Ryanodine (Ry) (B). (A-B) Representative traces for TG-induced Ca2+ 
release (left), and quantified results (right); n = at least 11 replicates per condition.  (C-D) 
INS-1 cells were treated with 5 ng/ml IL1β+25 mM glucose (ILHG) for 24 hrs with or 
without 5 µM XeC (C) or 100 µM Ry (D).  (C-D) Representative traces for the TG-
induced Ca2+ release (left), and quantified results (right); n = at least 15 readings per 
condition; *p ≤ 0.05; **p≤ 0.01; ***p≤ 0.001 compared to control conditions. §p ≤ 0.001 
for comparison between TM and TM + Ry. #p ≤ 0.05 for comparison between ILHG and 
ILHG + XeC.  
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Figure 7. Ryanodine treatment prevented TM-induced cell death 
(A) Caspase 3/7 activity was measured in INS-1 cells treated with 300 nM TM with or 
without 100 µM uM Ryanodine for indicated times; n = 4 replicates for each timepoint 
and condition. (B) Immunoblot analysis was performed in INS-1 cells treated with 300 
nM TM with or without 100 µM Ryanodine for indicated times using antibodies against 
cleaved caspase-3, and Actin.  Quantitative protein levels from three independent 
experiments are shown graphically.  (C) Caspase 3/7 activity was measured in INS-1 
cells treated with 5 ng/ml IL1β + 25 mM glucose (ILHG) for 24 hours; n = 4 replicates for 
each condition. **p ≤ 0.01 and ***p ≤ 0.001 compared to control conditions.  In (A), §p ≤ 
0.001 for the comparison between TM for 24 hrs and TM+Ry for 24 hrs.  In (B), #p ≤ 
0.05 and †p ≤ 0.01 for the comparisons between TM and TM + Ry for 24 and 36 hrs, 
respectively.   
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2.4 Reduction of ER Ca2+ leak via the RyR suppressed TM-induced Ca2+ transients 
and activation of the UPR  
Results thus far suggested a dominant role for RyR dysfunction under ER stress 
conditions, but primarily focused on bulk analysis of Ca2+ dynamics in large cell 
populations.  To define patterns of ER Ca2+ leak through the RyR in real-time at the 
single-cell level, spontaneous Ca2+ transients were measured in response to graded 
Ca2+ loading.  Ca2+ serves as the primary ligand of the RyR.  Spontaneous Ca2+ 
transients are observed in excitable cells, such as neurons and cardiac myocytes and 
have been shown to be coupled with ER Ca2+ leak through the RyR (287).  To date, this 
process has not been studied in the pancreatic β cell, either under normal or stress 
conditions. By increasing extracellular Ca2+ concentration up to 2 mM, oscillating and 
spontaneous Ca2+ transients were induced in 10.40 % ±1.54 % (S.E.M) of β cells under 
control conditions.  In response to TM-induced ER stress, the percentage of responding 
cells increased significantly, to a maximum of 55.74 % ± 6.67 % of cells after 12 hrs of 
treatment (Fig. 8A, C). Ryanodine co-treatment was found to significantly decrease TM-
induced Ca2+ transients (Fig. 8A, D), suggesting the ER Ca2+ leak was mediated through 
the RyR.  Notably, the response to caffeine, a pharmacological agonist of the RyR, was 
inhibited in the presence of 100 µM Ry (Fig. 8B), confirming that Ry was indeed acting 
through inhibition of RyR-mediated Ca2+ transients and cellular hyperexcitability.   
To define whether β cell depolarization contributed to these ER-stress induced 
Ca2+ transients, cells were hyperpolarized by diazoxide (Dz) to inhibit activation of 
voltage-dependent Ca2+ channels (VDCCs). In this context, spontaneous Ca2+ transients 
induced by tunicamycin were similarly reduced (Fig. 8E), suggesting that ER-stress 
induced Ca2+ transients originate from ER Ca2+ leak from the RyR as well as through 
secondary signals generated by Ca2+ influx through VDCCs.  
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Figure 8. ER Ca2+ dynamics regulated electrical activity of β cells 
 (A) Intracellular Ca2+ transients were measured in response to graded Ca2+ loading in 
INS-1 cells treated under control conditions (top), following treatment with TM for 12 hrs 
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(middle), or following co-treatment with TM + Ry for 12 hrs (both).  Data shown are 
representative of 30 single cell recordings from at least three independent experiments. 
(B) Traces show intracellular Ca2+ levels in INS-1 cells in response to caffeine treatment 
under control conditions and with ryanodine pre-treatment.  (C) Percentages (%) of 
responding cells in INS-1 cells treated with TM for 6 hrs (n= 2 replicates); 12 hrs (n = 5 
replicates); and 24 hrs (n = 4 replicates).  (C) The % of responding cells was significantly 
reduced by Ry co-treatment (n = 3 replicates per conditions).  (D) Representative trace 
indicates that spontaneous TM-induced Ca2+ transients were reduced by diazoxide (Dz).  
Data shown are representative of 15 single cell recordings.  *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 
0.001 for indicated comparisons. 
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During ER stress, cells activate an adaptive response known as the UPR in order 
to both clear unfolded proteins and increase the folding capacity of the ER (288). 
However, prolonged UPR activation eventually leads to apoptosis if cellular homeostasis 
is not restored (289,290). While UPR activation has been linked with ER Ca2+ loss (138), 
the temporal relationships and causal effects between UPR activation and ER Ca2+  loss 
remain poorly understood. To address, we first measured XBP1 mRNA splicing to 
validate this marker as an early upstream indicator of UPR activation.  An increase in the 
spliced to total XBP1 ratio was observed within 2 hrs of TM treatment and occurred prior 
to induction of both AFT4 and CHOP expression, which both increased around 6 hrs 
(Fig. 9A).  Next, time-course experiments were performed to define how suppression of 
ER Ca2+ leak from the RyR impacted UPR activation.  Our results revealed that 
ryanodine was able to significantly delay TM-induced UPR activation (Fig. 9B). To study 
this further, single-cell Ca2+ transients were measured at these early timepoints. 
Intracellular Ca2+ transients were found to increase within 3 hrs of TM treatment.  Similar 
to results obtained with chronic TM treatment, co-treatment with Ry was sufficient to 
suppress these Ca2+ transients (Fig. 9C-D), indicating that ER Ca2+ leak is an early 
response to misfolded protein accumulation that occurs prior to full expression of the ER 
stress signaling cascade.  Moreover, our results indicated that suppression of RyR-
mediated Ca2+ leak was sufficient to reduce propagation of the UPR.   
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Figure 9. Inhibition of RyR-mediated ER Ca2+ leak attenuated activation of the 
unfolded protein response 
(A) INS-1 cells were treated with 300 nM TM for indicated times, and mRNA levels of the 
spliced/unspliced XBP-1 ratio, ATF4, and CHOP were measured by RT-PCR. (B) The 
spliced/unspliced XBP-1 ratio was measured by RT-PCR in INS-1 cells treated with TM 
or TM+Ry for 3 hrs (left panel), 4 hrs (center), and 6 hrs (right panel). **p ≤ 0.01; ***p ≤ 
0.001 compared to time 0 or control conditions; †p ≤ 0.01 and §p ≤ 0.001 for 
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comparisons between TM and TM + Ry groups.  (C) Intracellular Ca2+ transients were 
measured in response to graded Ca2+ loading in INS-1 cells treated with TM for 3 hrs 
(top) or following co-treatment with TM+Ry for 3 hrs (bottom).  Data shown are 
representative of 30 single cell recordings with n=at least 3 replicates for each condition. 
(D) Quantification of the % of responding cells in INS-1 cells treated under controls 
conditions, with TM or with TM + Ry for 3 hrs; n = at least 3 replicates for each condition.  
*p ≤ 0.05; **p ≤ 0.01 for comparison between indicated groups. 
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2.5 Pharmacological inhibition of the RyR improved intracellular Ca2+ dynamics in 
TM-treated human islets and islets isolated from Akita mice 
To test whether these findings could be recapitulated in a human model system, 
dispersed cadaveric human islets were treated with tunicamycin and intracellular Ca2+ 
transients were measured.  Similar to results observed in INS-1 β cells, spontaneous 
Ca2+ transients were induced under ER stress evoked by TM, and ryanodine co-
treatment decreased TM-induced Ca2+ transients (Fig. 10A-B),  
Finally, we tested whether RyR inhibition would show similar result in an islet 
model of misfolded protein accumulation and ER stress (283,284). To this end, islets 
were isolated from 6-week old Akita mice and incubated with ryanodine or DMSO for 24 
hours.  Fura-2 AM imaging was performed to measure glucose-induced Ca2+ oscillations 
(GICOs).  GICOs were markedly diminished in Akita islets under control conditions, 
while treatment with ryanodine improved the oscillation frequency and area under the 
curve of the glucose-induced Ca2+ responses (Fig. 10C-E).  Moreover, Ry treatment 
significantly decreased the area of dead cells in islets from Akita mice (Fig. 10F-G). 
Finally, glucose stimulated insulin secretion (GSIS) was measured, the fold-increase of 
insulin secretion was the same between DMSO and Ry treated Akita islets. 
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Figure 10. Ca2+ signaling and cell death were rescued by ryanodine treatment in 
tunicamycin-treated human islets and islets from Akita mice 
0
2
4
6
D
ea
d 
C
el
ls
 (%
)
DMSO      Ry
**
0.6
0.7
0.8
Ryanodine
5 min
0.6
0.7
0.8
G15
G5
DMSO
Live Dead 
Figure 8.
C
F G
0
2
4
6
8
Fr
eq
ue
nc
y
DMSO      Ry 
***
0.0
0.2
0.4
0.6
Ar
ea
 U
nd
er
 C
ur
ve
 (A
.U
.)
DMSO      Ry
**
D E
Fu
ra
-2
 R
at
io
Fu
ra
-2
 R
at
io
DMSO Ryanodine
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
[Ca2+]ex (mM)
R
es
po
nd
in
g 
C
el
ls
 (%
)
Control
TM 6h
TM+Ry 6h
Control
[Ca2+]o(mM)
0.1             0.5                     1                             2          
TM6h
TM+Ry 6h
Fu
ra
-2
R
at
io
2 min
0.
2
A B
0
2
4
6
8
In
su
lin
 (F
ol
d 
In
cr
ea
se
)
LG
DMSO                         Ry 
LGHG HG
*
*
H
 
54 
(A) Representative data from 20 single cell calcium recordings performed in dispersed 
cadaveric human islets from a single biological donor analyzed under control conditions 
(top), following treatment with TM for 6 hrs (middle), and following co-treatment with TM 
+ Ry for 6 hrs (bottom).  (B) The % of responding cells was quantified for each condition.  
(C) Glucose-stimulated calcium oscillations were measured in islets isolated from Akita 
mice treated with DMSO or Ryanodine for 24 hrs.  Shown are representative recordings 
from 4 individual islets.  (D) The frequency of oscillations and area under curve for 
calcium responses (E) were quantified from 3 biological replicates per conditions.  (F) 
Representative pictures of Live (green) and Dead (red) staining performed in Akita islets 
treated with DMSO or Ryanodine for 48 hrs. (G) Quantification of the % of dead cells 
from n=3 replicates per condition. (H) Using Akita islets GSIS was measured after 
treating DMSO or 100 µM Ry for 48 hrs. LG indicates low-glucose treated group and HG 
indicates high-glucose treated group with n=3 replicates; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 
0.001 for comparisons between indicated groups. 
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Chapter 3. Discussion 
3.1 Summary and significance 
The Ca2+ concentration within the lumen of the β cell ER is estimated to be three 
orders of magnitude higher than intracellular Ca2+ levels.  Ca2+ within this cellular 
compartment serves as an essential cofactor for protein chaperones and foldases 
required for insulin processing, while Ca2+ release from the ER regulates glucose-
stimulated Ca2+ oscillations and phasic insulin secretion. Loss of ER Ca2+ has been 
shown to lead to impaired insulin secretion as well as activation of cell-intrinsic stress 
pathways including ER and oxidative stress and reduced β cell survival.  Whereas a 
prominent role for reduced β cell SERCA pump activity has been identified in diabetes, 
the question remains if alterations in RyR or IP3 function, which regulate ER Ca2+ 
release, similarly contribute to these processes.  
To test this, we applied intracellular and ER- Ca2+ imaging techniques to 
measure ryanodine receptor (RyR) and inositol 1,4,5-triphosphate receptor (IP3R) 
activity in response to two distinct stress paradigms known to contribute to the 
pathogenesis of both type 1 and type 2 diabetes.  The stress paradigms tested were ER 
stress, which was induced chemically using tunicamcyin in INS-1 β cells and in 
cadaveric human islets. Aspects of our model were also evaluated in islets from Akita 
mice, a strain harboring a spontaneous mutation in one allele of the INS2 gene, resulting 
in impaired proinsulin folding and severe ER stress (283,284).  To recapitulate pro-
inflammatory cytokine induced dysfunction, INS-1 cells were treated with high glucose 
(25 mM glucose) in combination with IL-1β, a cytokine known to be systemically elevated 
in diabetes.  In aggregate, our results revealed a preferential sensitivity of the RyR to ER 
stress, while pro-inflammatory cytokine stress was found to primarily impact IP3R 
activity. Pharmacological inhibition of the RyR with ryanodine and inhibition of the IP3R 
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with xestospongin C were both able to prevent ER Ca2+ loss under these respective 
stress conditions.  However, inhibition of RyR-mediated Ca2+ loss was distinct in its 
ability to prevent β cell death.  Additional analysis showed that RyR inhibition also 
delayed the initiation of the UPR and an improvement of glucose-induced Ca2+ 
oscillations and insulin secretion.   
The RyR is a large macromolecular complex that is primarily localized to the ER 
or sarcoplasmic reticulum membranes.  The RyR remains closed at low intracellular Ca2+ 
concentrations.  However, as intracellular Ca2+ levels increase in the range of 0.01-20 
uM, Ca2+ binds the receptor, leading to channel opening and ER Ca2+ release (179). . In 
addition to ligand binding, channel activity is modulated by a number of interacting 
proteins contained within this macromolecular complex (156-159). RyR was found to be 
expressed on the surface of β cell dense core secretory vesicles (291), and two 
independent groups have demonstrated secretory vesicle Ca2+ release in response to 
RyR activation, (291) indicating the RyR may also regulate localized Ca2+ signals 
responsible for granule exocytosis.    
RyR dysfunction has been well-documented in a number of other disease states 
including cancer-associated muscle weakness (153), Alzheimer’s disease (171), and 
cardiomyopathy (164). In contrast, only a handful of studies have investigated whether β 
cell RyR dysfunction contributes to the diabetes pathophysiology. Luciani and 
colleagues found that both RyR and IP3R inhibition were able to attenuate thapsigargin-
induced ER stress in MIN6 β cells (211). This approach caused ER stress by inducing 
ER Ca2+ loss, therefore this does not likely show how ER stress affect ER Ca2+ 
dyanamics and cell death. To address this, we have induced ER stress directly by using 
TM, and our analysis was uniquely able to distinguish the impact of two different stress 
paradigms on RyR and IP3R activity and function, a topic unaddressed in previous 
studies.  Our results indicate that RyR dysfunction is uniquely induced by misfolded 
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protein accumulation, while pro-inflammatory cytokine stress had little impact on RyR 
function.  In support of our findings, the RyR antagonist, dantrolene, was previously 
shown to reduce cell death in INS-1 β cells lacking WSF1 protein, another model of 
severe ER stress (212).   
To document the mode of RyR dysfunction in response to ER stress, we 
measured spontaneous intracellular Ca2+ transients at the single cell level in response to 
graded increase in extracellular Ca2+.  Our results indicate that ER-stress lowers the 
threshold and frequency of RyR-mediated ER Ca2+ release in both INS-1 cells and 
cadaveric human islets. We also found these ER-stress induced Ca2+ transients were 
composed of both ER Ca2+ release and Ca2+ influx through VDCCs, thus contributing to 
an overall state of β cell hyperexcitability. These results are consistent with findings in 
other excitable cells and pathologic states. For example, prion as well as amyloid-beta 
protein accumulation in cortical neurons has been shown to lead to ER stress, ER Ca2+ 
release from the RyR, and increased neuronal excitability (292).    
A handful of molecular pathways have been implicated as potential contributors 
to β cell RyR dysfunction. Mice with a mutated form of the RyR2 leading to constitutive 
CaMKII-mediated phosphorylation and chronic RyR2 gain of function exhibited impaired 
glucose-induced insulin and Ca2+ responses as well as glucose intolerance (293).  
Similarly, RyR mutations that lead to dissociation of calstabin2 have been shown to lead 
to RyR gain of function, resulting in a condition known as catecholaminergic polymorphic 
ventricular tachycardia (CVPT) in humans. Mice expressing two mutated forms of the 
RyR2 associated with CVPT were shown to be glucose intolerant. Isolated islets 
exhibited decreased glucose-stimulated insulin secretion and impaired mitochondrial 
metabolism.  Intriguingly, humans with CPVT were found to have higher glucose levels 
and lower insulin levels during an oral glucose tolerance test compared to age and BMI-
matched controls (210). Oxidative stress has been shown to contribute to both calstabin 
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dissociation from the RyR as well CaMKII-mediated RyR phosphorylation.  Indeed, 
alterations in calstabin and RyR association have been demonstrated in islets from 
donors with Type 2 diabetes (210).  Recently, loss of sorcin, a Ca2+ sensor protein that 
inhibits RyR activity, was similarly shown to lead to glucose intolerance, while sorcin 
overexpression improved GSIS and ER Ca2+ storage. Palmitate-induced lipotoxicity 
decreased sorcin expression in human and mouse islets (294). Interestingly, in a model 
of Parkinson’s disease, ER stress itself led to aberrant accumulation of RyR, resulting in 
increased ER Ca2+ release (295).  Thus, whether RyR dysfunction occurs secondary to 
loss of stabilizing or inhibitory protein, through impaired receptor degradation, or through 
yet another distinct mechanism in the pancreatic β cell will be explored in future studies.  
Notwithstanding this unknown, our data suggests that targeting the RyR receptor has the 
potential to improve β cell survival through attenuation of ER stress as well and β cell 
function through restoration of glucose-induced Ca2+ oscillations and improved insulin 
secretion (Fig. 11). Drug discovery efforts are actively done aimed at identifying small 
molecular RyR-stabilizers (296).  In aggregate, our data suggest such compounds may 
have utility in improving the health of the diabetic β cell.    
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Figure 11. Model for protecting ER Ca2+ dynamics by RyR inhibition under ER 
stress 
ER stress leads to RyR-mediated ER Ca2+ leak, while inhibition of RyR-mediated ER 
calcium loss restores ER Ca2+ dynamics, glucose-stimulated calcium oscillations and 
attenuates UPR activation and cell death.  (A) Our data indicate that under ER stress 
conditions, RyR function is disrupted, leading to decreased ER Ca2+ storage and altered 
ER Ca2+ dynamics.  As a consequence, cellular excitability and GICOs are disrupted and 
activation of the UPR is increased, eventually leading to cell death. (B) Inhibition of RyR-
mediated loss of ER Ca2 leads to a partial rescue of ER Ca2+ dynamics under ER stress 
conditions. This leads to improved cellular excitability, improved GICOs, delayed 
initiation of the UPR, and improved cellular survival.   
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3.2 Limitations and Future Study 
3.2.1 Techniques to measure ER Ca2+ dynamics 
In the current research, we have estimated free ER Ca2+ concentration in 
populations of β cells under stress conditions by measuring the increase in intracellular 
Ca2+ following pharmacological inhibition of SERCA in Ca2+ free extracellular solutions 
using the calcium indicator, Calcium 6. SERCA inhibition results in passive ER Ca2+ 
release from RyR and IP3R until ER Ca2+ is depleted (Fig. 3). The kinetics of ER Ca2+ 
release induced by TG is slow process due to the passive release from RyR and IP3R 
and reaches a peak fluorescent intensity in tens of seconds to minutes.  The kinetics of 
this process is also affected by the function of plasma membrane ion transporters such 
as PMCA and NCX whose function may also have been altered by the stress conditions 
(297). While this technique is widely accepted, inhibition of plasma membrane and 
organellar Ca2+ transporters would have given better estimation especially when it 
comes to the small change induced by weaker stress. 
Furthermore, TG induced minimal elevations in intracellular Ca2+ in intact islets, 
so estimation of ER Ca2+ levels in islets was not successfully using this approach. Within 
the islets, β cells are known to be physically connected through gap junction channels 
(278) and the increase in intracellular Ca2+ is likely buffered by neighboring cells. In 
addition, TG simply may not penetrate cells inside the islet. Therefore, techniques to 
directly measure ER Ca2+ concentration more reliably should be considered. 
We also measured directly ER Ca2+ release by using low affinity Ca2+ indicator, 
Mag-fluor 4 AM (Fig. 4 and 5). This was a technique that enabled a high-throughput 
format and was beneficial in making dose-response curves with agonists. Although this 
directly measured Ca2+ in ER, imaging was done after permeabilization of plasma 
membrane and by studying population of cells.  
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The approaches taken above can capture only one aspect of ER Ca2+ such as 
ER Ca2+ concentration or ER Ca2+ release. These approaches do not capture ER Ca2+ 
dynamics, which are more relevant to physiological activities. Our approach to measure 
spontaneous intracellular Ca2+ transients provides some insight into ER Ca2+ dynamics, 
and showed that bursts of ER Ca2+ release increased under ER stress conditions (Fig. 
8). Nevertheless, the techniques that can reliably detect ER Ca2+ dynamics by directly 
measuring ER Ca2+ will be beneficial, which will be discussed in the future direction.  
 
3.2.2 Basis of RyR and IP3R dysfunction 
 Our results from functional assays showed that RyR function was altered under 
ER stress, while IP3R function was preferentially altered under pro-inflammatory stress 
conditions (Fig. 4 and 5).  This data was supported by results showing that ER Ca2+ loss 
induced by these respective stress conditions were rescued by inhibiting RyR under ER 
stress conditions and IP3R in response to pro-inflammatory stress (Fig. 6 and 7). This 
approach enabled us to document receptors dysfunction. However, the basis of the 
dysfunction was not addressed in the current study.  This information will be crucial in 
order to identify more specific drug target.  
Possible molecular mechanisms that may cause changes in overall receptor 
function include changes in expression levels and post-translational modifications. The 
known regulation of RyR and IP3R by post-translational modification was summarized in 
detail in the Introduction section. For instance, RyR undergoes phosphorylation and 
oxidation, and nitrosylation that can cause dissociation of RyR stabilizing protein 
calstabin resulting in Ca2+ leak from ER (298-300). It is likely that ER stress may have 
induced one of these modifications, leading to ER Ca2+ release and increased 
intracellular Ca2+ transients that exacerbate UPR activation and lead to cell death. 
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Inhibition of RyR by Ry under ER stress conditions may have mitigated the deleterious 
effects of these post-translational modifications. Our result showed that S107, which 
stabilizes the RyR and calstabin interaction did not restore the ER Ca2+ under ER stress 
(Fig. 12). This indicates either ER stress was robust enough to nullify the effects of S107 
or that other post-translational modifications were involved in this process. These 
possibilities could be tested in future studies. 
Likewise, IP3R can be regulated by phosphorylation or by the binding of 
associated proteins to its regulatory domain. For instance, PKA activation leads to an 
opening of IP3R (301,302). Therefore, a more thorough understanding of the effects of 
post-translational modifications will be necessary. In addition, these results may need to 
be studied within the context of ER Ca2+ dynamics, because efforts to stabilize the 
calstabin interaction or prevent oxidative stress, for example, may impact spontaneous 
ER Ca2+ release without being able to restore ER Ca2+. 
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Figure 12. ER Ca2+ loss was not prevented by the RyR stabilizer S107 under ER 
stress conditions 
INS-1 cells were treated with 300nM TM for 24 hours with or without 10 µM S107; n = at 
least 3 replicates per condition; ***p≤ 0.001 compared to control conditions.  
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3.2.3 Limitations arising from the use of rodent models 
 The current study was performed using cell lines and through ex vivo analysis of 
islets from rodent models. These models may not necessarily recapitulate in vivo 
findings. Therefore, key aspects of our model need to be confirmed using in vivo models 
and in human islets and humans. There are considerable difference even in islets 
between mouse and humans. In a mouse islet, α cells reside mostly on the surface of an 
islet, while β cells tend to be more in the center of the islet (303). In contrast, α cells and 
β cells are equally distributed throughout the human islet (303). In addition to localization 
within islets, channels regulating to Ca2+ dynamics and action potentials in β cells are 
different between mice and human. For instance, human and mouse β cells both 
express Na+ channels. Na+ channels in human β cells amplify action potentials (47), but 
the Na+ channels in mouse β cells has minimal effects (251). P/Q-type Ca2+ channels 
and L-type Ca2+ channels (Cav 1.2 and 1.3) elicit about 40% of Ca2+ current each in 
human β cells (47), but L-type Ca2+ channels elicits more than 60% of total Ca2+ current 
in mouse β cells and P/Q-type Ca2+ channels have minimal effects (251). 
 In addition, in vivo plasma glucose levels are continuously fluctuating, and β cells 
will be exposed to a countless number of molecules such as hormones, lipids or 
cytokines that can regulate channel activities and as well as cellular activities. To make 
matters more complicated, there are neuronal innervations to islets and β cells. These 
include efferent neurons coming from brain as well as inter and intra-islet neuronal 
networks (304). Therefore, studying β cell function in vivo is crucial.   
Finally, our apoptosis or cell death assay was difficult to apply to islets. This may 
be because islets the expression levels of proteins related to apoptosis are low, or 
macrophages clear dead cells fairy quickly (305). Therefore studying in vivo with all 
these things could tell you more about the relevance of human diseases. 
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3.2.4 Future directions 
Studying ER Ca2+ dynamics in islets or β cells is challenging due to the 
limitations with currently available techniques mentioned above. The genetically-
encoded Ca2+ indicator D4ER maybe able to resolve the problem, however islet cells 
exhibits autofluorescence when excited at blue or green light (~430-490 nm) (306), 
which will cross contaminate and mask the fluorescence of D4ER  (Ex. 435 nm, Em. 540 
and 475 nm), which is the fluorescent Förster resonance energy transfer (FRET)- based 
ER Ca2+ indicator widely used. To solve the issue with autofluorescence, a Ca2+ indicator 
with other wavelengthes such as mCherry CEPIA (307), or bioluminescence resonance 
energy transfer (BRET)- based Ca2+ indicator (308) would be worthwhile options. BRET 
is advantageous because it does not require any excitation light, and does not undergo 
photobleaching because of illumination. 
To overcome the limitations with in vitro studies, it will be beneficial to perform 
experiments in vivo. To conduct Ca2+ imaging in vivo, our lab has recently generated an 
insulin Cre-induced GCaMP6s mouse line. Using this line, we can express GCaMP6s, 
which are genetically encoded high affinity Ca2+ indicator, in β cells. Our approach could 
be to apply intravital microscopic techniques to image the mouse pancreas (309,310). 
With this approach, pancreata will be surgically exposed outside the body and the 
pancreas can be imaged using two-photon microscopy. With this technique, Ca2+ 
oscillation in vivo could be studied and this will greatly advance the field to study 
hormonal, neuronal, and pharmacological regulation of Ca2+ in β cells. To follow up the 
current study, mouse with inducible RyR knockout model under stress conditions could 
be used to replicate what we found in β cell line and mouse pancreatic islets.   
This intravital microscopy will be beneficial not only for the Ca2+ imaging, but can 
also be applied to visualize many other biological assays. For instance, the apoptosis 
and cell death assay could be tested in vivo, and the interactions of immune cells could 
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be clarified by also visualizing macrophages. Furthermore, UPR marker such as Xbp1 or 
Chop could be visualized in vivo as well. 
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Chapter 4. Materials and Methods 
4.1 Materials 
4.1.1. Animals, islet isolation and human islet preparation 
a. Mice 
C57BL/6J (WT) mice, Akita mice, are db/db mice were obtained from Jackson 
Laboratories (Bar Harbor, ME) at 5 - 10 weeks of age, and maintained under protocols 
approved by the Indiana University Institutional Animal Care and Use Committee, the 
U.S. Department of Agriculture’s Animal Welfare Act (9 CFR Parts 1, 2, and 3), and the 
Guide for the Care and Use of Laboratory Animals  
b. Human islets  
Human cadaveric islets isolated from non-diabetic donors were obtained from the 
Integrated Islet Distribution Program or the National Disease Research Interchange.  
Upon receipt, human islets were hand-picked and allowed to recover overnight in 
Dulbecco’s modified essential medium (DMEM) medium containing 5.5mM glucose, 
10% fetal bovine serum (FBS), 100U/ml penicillin, and 100µg/ml streptomycin. 
4.1.2 Cell culture and islet isolation 
INS-1 832/13 rat insulinoma cells were cultured in regular 11mM glucose Roswell 
Park Memorial Institute medium (RPMI) 1640 supplemented with 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, 1mM sodium pyruvate, 
50µM β-macaptoethanol and, 10% FBS, penicillin and streptomycin.  
Mice islets were isolated by collagenase digestion as described previously (311). 
The islets were hand-picked, and allowed to recover overnight in regular RPMI 
supplemented with 10% FBS, 100U/ml penicillin, and 100µg/ml streptomycin. 
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4.1.3. Primers, antibodies and reagents 
Standard polymerase chain reaction (PCR) reactions for quantitative PCR 
(qPCR) for gene expressions were performed using oligonucleotides synthesized by 
Invitrogen (Table 3).  
Antibodies used in western blotting, immunofluorescent and 
immunohistochemistry staining are listed in Table 2. Chemicals and reagents used in 
the research are listed in Table 4.  
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Table 2. Antibodies for Western Blotting and Immuno-staining 
Targeted protein Host Species Manufacturer Dilution 
Total caspase 3  Rabbit Cell Signaling 1:1000 
Mouse IgG (IRDye 800CW) Donkey Li-cor 1:10000 
 
 
70 
 Table 3. Quantitative RT-PCR Primers 
Gene Species Forward (5’-3’) Reverse (5’-3’) 
Total Xbp-1 Rattus rattus AGCACTCAGACTACGTGCGCCTC CCAGAATGCCCAAAAGGATATCAG 
Spliced Xbp-1 Rattus rattus CTGAGTCCGCAGCAGGT TGTCAGAGTCCATGGGAAGA 
ATF4 Rattus rattus GTTGGTCAGTGCCTCAGACA CATTCGAAACAGAGCATCGA 
CHOP Rattus rattus CCAGCAGAGGTCACAAGCAC CGCACTACCACTCTGTTTC 
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Table 4. Chemicals and Reagents 
Name Manufacturer 
Caffeine Santa Cruz  
D-Glucose Sigma-Aldrich 
Hanks' Balanced Salt Solution (HBSS) Lonza 
D-myo-Inositol-1,4,5-triphosphate hexapotassium salt (IP3) Santa Cruz 
Xestospongin C Santa Cruz 
Tunicamycin Cayman Chemicals 
Thapsigargin Cayman Chemicals 
Fura-2-acetoxymethylester (Fura-2 AM) Thermo Fisher 
Mag-Fluo-4 AM Thermo Fisher 
Mouse IL-1 beta Recombinant Protein (IL-1β) Thermo Fisher 
Diazoxide Sigma-Aldrich 
Dantrolene Sigma-Aldrich 
Adenosine 5’-triphosphate magnesium salt (ATP) Sigma-Aldrich 
Ryanodine Tocris 
Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) Tocris 
Calcium 6 Molecular Devices 
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Table 5. Ca2+ indicators and Wavelengths 
Name Excitation and Emission Wavelength Manufacturer 
Calcium 6 Ex. 490 nm, Em. 525 nm Molecular Devices 
Fura 2AM Ex. 340 and 380 nm, Em. 510 nm Thermo Fisher 
Mag-fluor 4AM Ex. 490 nm, Em. 525 nm Thermo Fisher 
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4.2 Methods 
4.2.1 Animal studies and cell culture 
Male C57BL/6J, heterozygous Ins2Akita (Akita), and C57BLKS-homozygous 
Leprdb (db/db) mice were obtained from Jackson Laboratories (Bar Harbor, ME) and 
maintained under protocols approved by the Indiana University Institutional Animal Care 
and Use Committee.  Mice were kept in a standard light-dark cycle with ad libitum 
access to food and water. Pancreatic islets were isolated by collagenase digestion, 
hand-picked, and allowed to recover overnight as described previously (311). INS-1 
832/13 rat insulinoma cells were maintained according to previously published protocols 
(312,313).   
 
4.2.2 Immunoblot and quantitative PCR  
Immunoblot experiments were performed as described (314). In brief, cells were 
lysed in 1% IGEPAL reagent supplemented with 10% glycerol, 16 mM NaCl, 25 mM 
HEPES, Sigma-Aldrich, St. Louis, MO), 60 mM n-octylglucoside (Research Products 
International Corp.), phosphatase inhibitor cocktails (PhosSTOP tablets, Roche) and 
phosphatase inhibitor cocktails (EDTA-free cOmplete tablets, Roche). Protein 
concentration was measured using the Bio-Rad DC protein assay (Bio-Rad, Hercules, 
CA) and a SpectraMax M5 multiwell plate reader (Molecular Devices, Sunnyvale, CA). 
Equal concentrations of proteins were suspended in 10% SDS solution. Protein lysates 
were electrophoresed and transferred to methanol-activated PVDF membrane 
(Immobilon-FL Transfer Membrane from Millipore). Membranes were then blocked with 
Odyssey blocking buffer (LI-COR, Lincoln, NE) prior to incubation with primary 
antibodies listed in Table 2. Subsequently, membranes were incubated with IRDye 800 
or 680 fluorophore-labeled secondary antibodies from LI-COR. The total protein levels 
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were normalized to actin protein levels. Images were analyzed using LI-COR Image 
Studio and Image-J software (National Institutes of Health, Bethesda, MD, USA). 
For qPCR, Cultured cells or isolated islets were processed for total RNA using 
the Qiagen RNeasy Mini Plus kit (Valencia, CA, USA). For reverse transcription-PCR 
experiments, total RNA was processed using Moloney murine leukemia virus (MMLV) 
reverse transcriptase (Invitrogen, Grand Island, NY). Subsequently, qPCR was 
performed using JumpStart™ Taq DNA Polymerase (Sigma-Aldrich, St. Louis, MO), and 
using SYBR Green I dye and previously published methods (312). Primers used for 
qPCR is listed in Table 3. 
 
4.2.3 Stress simulation 
To mimic the pro-inflammatory stress milieu of diabetes, cells and mouse islets 
were treated in RPMI media containing 5 ng/mL of mouse IL-1β for indicated times. To 
mimic the ER stress in diabetic milieu, INS-1 cells or mouse islets were cultured in RPMI 
containing 300 nM TM with indicated times. 
 
4.2.4 Intracellular calcium (Ca2+) imaging 
Intracellular Ca2+ was measured using the FLIPR Calcium 6 Assay Kit and the 
Molecular Devices FlexStation 3 system (Sunnyvale, CA, USA) or using the ratiometric 
Ca2+ indicator Fura-2 AM as previously outlined (315). In brief, INS-1 832/13 cells were 
plated in black wall/clear bottom 96-multiwell plates from Costar (Tewksbury, MA, USA) 
and cultured for 2 days. Following drug or stress treatment, cells were transferred to 
Ca2+ free Hanks’ balanced salt solution from Lonza (Basel, Switzerland) supplemented 
with 0.2% BSA and EGTA. Calcium 6 reagent was added directly to cells, and cells were 
incubated for an additional 2 hours at 37  °C and 5% CO2. ER Ca2+ was estimated by 
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measuring the increase of intracellular Ca2+ upon application of 10 µM thapsigargin (TG). 
Data acquisition on the FlexStation 3 system was performed at 37°C using a 1.52-  s 
reading interval with an excitation wavelength of 485 nm and emission wavelength of 
525 nm. For data analysis, values derived from the TG response (ΔF) were divided by 
resting intracellular calcium [Ca2+]i (F0), using the formula ΔF/ F0.  Fura-2 AM 
fluorescence intensity was measured using an excitation wavelength of 340 nm and 380 
nm and an emission wavelength of 510 nm.  Images were captured using a Zeiss Z1 
microscope with a 10x or 20x objective. Spontaneous intracellular Ca2+ transients were 
measured using the method described by Tang et al (287). Briefly, INS-1 cells or 
dispersed mouse islets were imaged under Ca2+ free conditions using Fura-2AM. 
Extracellular Ca2+ was increased in a step-wise fashion to evoke Ca2+ transients until a 
physiological extracellular Ca2+ concentration of 2mM was reached. Data were analyzed 
using Zeiss Zen Blue software (Oberkochen, Germany). The wavelength used for this 
experiment is summarized in Table 5.  
 
4.2.5 IP3R and RyR functional assays 
IP3R and RyR activation were evaluated in response to IP3 and caffeine, 
respectively using modifications to the protocol described by Tovey and Taylor (285). 
INS-1 cells were loaded with the low-affinity Ca2+ indicator, Mag-Fluo-4 AM followed by 
permeabilization of the plasma membrane with 10 µg/ml saponin, leaving Mag-Fluo-4 
AM in the lumen of cellular organelles. Data acquisition on the FlexStation 3 system was 
performed at 37°C using a 1.52-  s reading interval, with an excitation wavelength of 490 
nm and an emission wavelength at 525 nm. To establish steady-state ER Ca2+ levels, 
1.5mM Mg-ATP was added; then IP3 or caffeine were applied at the indicated 
concentrations to activate IP3R and RyR respectively. 
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4.2.6 Cell death assays and insulin secretion 
To measure Caspase 3/7 activity, INS-1 cells were cultured in black wall/clear 
bottom 96-multiwell plates for 2 days.  Following drug or stress treatment, Caspase-Glo 
reagent (Promega, Madison, WI) was added directly to cells, and cells were incubated 
for an additional 30 minutes at room temperature. The luminescence of each sample 
was measured by using a SpectraMax M5 microplate reader (Molecular Devices).  Cell 
viability in mouse islets was quantitated using the Live/Dead Cell Viability Assay from 
Thermo Fisher (Waltham, MA), according to the manufacturer’s instructions. Images 
were acquired using a Zeiss LSM 510 confocal microscope, and the area of dead cells 
was calculated by the ratio of ethidium homodimer-1 positive red area (Dead) and 
calcein-AM positive green area (Live). Glucose-stimulated insulin secretion was 
measured in isolated mouse islets as previously described.  Insulin secretion into the 
supernatant was normalized to DNA concentration, and insulin was measured using a 
mouse insulin ELISA from Mercodia (Uppsala, Sweden) (54,316). 
 
4.2.7 Statistical analysis 
Results are displayed as the means ± S.E.M.  GraphPad Prism Software (La 
Jolla, CA, USA) was used to fit data from IP3R and RyR functional assays to sigmoidal 
dose-response curves.  Differences between groups were analyzed for significance 
using GraphPad Prism Software and an unpaired Student’s t-Test or one-way ANOVA 
with Tukey-Kramer post-test.  A p value < 0.05 was used to indicate a significant 
difference between groups. 
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